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INTRODUCTION 

Rheumatoid arthritis (RA) is a chro-nic systemic disease affecting 1% to 
2% of the population. Its etiology is un-
known. Polyarthritis leading to joint 
damage and functional impairment is its 
main clinical feature. In managing RA 
patients drug treatment plays a key role. 
Additional support may include physical 
therapy, ergotherapy, nursing and car-
ing, social support and orthopedic sur-
gery. Non-Steroidal Anti-Inflammatory 
Drugs (NSAIDs) have a fast suppressive 
effect on inflammation, pain and stiff-
ness. Unfortunately, they have no influ-
ence on the progression of joint damage. 
Disease Modifying Anti-Rheumatic 
Drugs (DMARDs), also called second-
line antirheumatic drugs, on the other 
hand, are assumed to influence the dis-
ease process in a more fundamental way 
and to slow the progression of joint dam-
age. Another feature of DMARDs is that 
the response to therapy can be evaluated 
only after 12 to 20 weeks. 
An important restriction in applying 
DMARDs is that a substantial percenta-
ge of patients have to be taken off these 
drugs because of lack of efficacy or major 
side effects. In such cases a period of 
persisting disease activity may follow, in 
which the development of irreversible 
joint damage continues. Knowledge of 
factors predicting response to DMARDs 
on the one hand and of toxicity on the 
other could provide a better risk-benefit 
ratio and could reduce the number of 
times a patient has to be exposed to such 
a lag time. The main objective of this 
study was to look for risk factors or com-
binations of factors predicting toxicity. 
For this purpose, side effects were de-
scribed and investigated thoroughly in a 
longitudinal prospective study. 
Until now only a few factors predicting 
efficacy have been described. For in-
stance presence of HLA-DR3 antigen 
has been related to good results of par-
enteral gold treatment. With respect to 
side effects many risk factors have been 
reported in the literature. However, the 
sensitivity and specificity of these risk 
factors in predicting the occurrence of 
adverse effects in a given patient are low; 
therefore, the clinical usefulness of these 
factors is rather limited. The literature 
regarding risk factors for DMARD tox-
icity will be reviewed in chapter 2 of the 
present thesis. 
Adverse drug reactions (ADR) are unin-
tended effects, varying from subclinical 
changes in laboratory assessments to life-
threatening events, caused by drugs in 
therapeutic doses. ADR can be divided 
into two groups: the more or less predict-
able 'toxic' and the unpredictable 'aller-
gic' or 'hypersensitivity' reactions. The 
former are often dose-dependent and re-
lated to the known intrinsic action of the 
drug. The latter are mostly unrelated to 
the dose or pharmacologic action of the 
drug, and often related to the patient's 
(immunologic, genetic) susceptibility. 
Since laboratory and clinical tests to con-
firm a causal relationship between a clin-
ical manifestation and an incriminated 
drug are generally lacking, adequate cri-
teria for adverse drug reactions arc 
needed. In an extensive article Stephens 
reviewed 22 methods for causality assess-
ment described in the literature. They 
vary from a simple questionnaire to a 
complex flow chart, laborious to fill out. 
Most are based on the time relationship, 
the course and the exclusion of alterna-
tive causes. It is shown that using the 
algorithms may improve the intra- and 
interobserver agreement. 
An example of an adverse drug reaction 
restricted to subclinical laboratory as-
sessments is the occurrence of hemolysis 
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during sulfasalazine treatment (chapter 
3). The consequence of this phenomenon 
for hemoglobin as a disease activity indi­
cator, and therefore for the proper man­
agement of sulfasalazine-treatcd RA pa­
tients is also evaluated. 
Chapter 4 comprises two case reports 
describing the occurrence of ADR en­
countered during second-line antirheu­
matic treatment. A probable relationship 
with certain risk factors (low IgA and 
HLA-DR3) is discussed. 
The occurrence of untoward reactions 
during antirheumatic drug treatment was 
investigated in co-operation with the 
University Hospital of Groningen in a 
long-term prospective study of patients 
with recent onset ( < 1 year) rheumatoid 
arthritis. The patients were treated ac­
cording to the same protocol by rheuma-
tologists of both centres. In addition, they 
were seen monthly by specially trained 
research nurses who collected quantita­
tive clinical and laboratory data. The use 
of drugs and side effects encountered 
were recorded using specific data collec­
tion forms. Because of its good inter- and 
intra-rater reliability, its content and 
concurrent validity and its easy and quick 
applicability the algorithm described by 
Naranjo et al. was chosen as a method 
for causality assessment for each side 
effect. Clinical features of gold-induced 
dermatitis, developed during this long-
term follow-up study, and its possible 
relationship with contact hypersensitivity 
to nickel are described in chapter 5. 
Since rheumatoid arthritis is a progres­
sive and protracted disease, necessitat­
ing drug treatment for many years, it is 
important to be informed on efficacy and 
toxicity of anti-rheumatic drugs on a 
long-term basis. Based on the data from 
the long-term prospective study the du­
ration of treatment, as well as the reasons 
for discontinuation of both NSAIDs and 
DMARDs were studied using the 
method of survival analysis (NSAIDs: 
chapter 6; DMARDs: chapter 7). 
The sensitivity and specificity of the risk 
factors mentioned in chapter 2 in pre­
dicting the occurrence of adverse effects 
in a given patient are low. In the long-
term study special attention was paid to 
the occurrence and characteristics of 
ADR. In addition, factors influencing 
treatment discontinuation were studied. 
These factors are described in chapter 8. 
It is often assumed that the disease rheu­
matoid arthritis itself may predispose to 
drug-induced toxicity. We conducted a 
meta-analysis evaluating discontinuation 
of sulfasalazine treatment because of 
side effects in patients with rheumatoid 
arthritis compared with patients with in­
flammatory bowel disease and patients 
suffering from seronegative spondylar-
thropathy. The results of this study are 
presented in chapter 9. 
The main conclusions of this thesis are 
summarized in chapter 10. 
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Drugs play an important role in the treatment of patients with rheumatoid arthritis. Unlike nonsteroidal antiinflammatory drugs (NSAIDs), disease modifying anti-
rheumatic drugs (DMARDs) are assumed to influence the disease process and to 
slow the progression of joint damage. Sometimes they induce a remission of the 
disease. An important restriction in applying DMARDs is that drug treatment must 
be abandoned in patients because of inefficacy or serious side effects. Several studies 
have shown that up to 70% of the patients have to stop treatment within two years. 
Another feature of DMARDs is the delayed onset of action which varies from 6 to 12 
weeks or longer. In this period of persisting disease activity, the development of 
irreversible joint damage continues. Knowledge of factors predicting response to 
DMARDs could improve the risk-benefit ratio of exposing patients to such treatment. 
Until recently only a few factors predictive of DM ARD efficacy have been described. 
For example, the presence of HLA-DR3 antigen has been related to good results of 
parenteral gold treatment. However, no such relation was found in other studies. ' 
With respect to side effects many risk factors have been described. Risk factors 
associated with genetics, with pharmacokinetics, immunologic variables and others 
will be reviewed. Side effects caused by overdose and commonly known hazards and 
contraindications, such as renal impairment and interactions with other drugs than 
DMARDs are not discussed. 
RISK FACTORS RELATED TO 
GENETICS 
The HLA marker described most consis-
tently in connection with gold and d-pe-
nicillamine toxicity is the HLA-DR3 an-
tigen.7'10·19 The relative risk (RR) of de-
veloping side effects varies in several re-
ported studies and depends on the kind 
of adverse reaction. In general, the RR is 
too low (less than about 10 times) to be 
of clinical importance in the care of the 
individual patient. Of interest is the in-
creased risk of agranulocytosis in HLA 
B27 positive patients treated with leva-
misóle. " Correlations with several 
other HLA antigens and certain side ef-
fects have been reported but are less con-
sistent.14·23·26 
27 
In a retrospective study Kay and Jayson 
reported a higher frequency of gold sto-
matitis in women than in men. Although 
methotrexate (MTX)-induccd pneumo-
nitis was not related to gender in one 
study, Searles and McKendry found 
a preponderance of men in their report 
of 10 RA patients with this complication. 
RISK FACTORS RELATED TO 
DOSAGE AND 
PHARMACOKINETICS 
Gold. A study^ comparing a high dose 
scheme of parenteral gold (100 mg twice 
a week) with a low dose scheme (25 mg 
twice a week) showed that adverse reac-
tions, particularly albuminuria, occurred 
more frequently in the high dose than in 
the low dose group. On the other hand, 
prospective studies comparing doses of 
50 mg and 25 mg, 10 mg and 1 mg/kg body 
weight weekly, respectively found no sta-
tistically significant differences in toxic-
ity. " No differences between a high 
(183 mg/month) and a low (56 mg / 
9 
month) maintenance dose were ob-
served in another study" 
Chrysiasis, a protracted or permanent 
grey-bluish discoloration of the sun-ex-
posed skin in particular, correlates with 
cumulative gold dosage. ' Chrysiasis 
has never been seen in patients given a 
total dose less than 18 mg/kg elemental 
gold or 50 mg/kg gold salt, but develops 
without exception in patients given a cu-
mulative dose higher than 55 mg/kg 
elemental gold or 150 mg/kg gold salt. 
Sunlight exposure" and previous 
gold-induced dermatitis ' have been 
described as predisposing factors. Gold 
deposition in the cornea, corneal chry-
siasis, also correlates with total dosage, 
and is likely to occur at cumulative doses 
of approximately 1.5 g gold salt. Unlike 
the corneal inflammation and ulceration 
due to gold therapy, such chrysiasis is 
harmless and does not impair vision. 
Although one study reported a weak 
relationship between corneal deposits 
and other gold side effects, there is no 
agreement on this subject. 
Oral gold. The major adverse reaction to 
oral gold (auranofin), the occurrence of 
loose stools, probably due to a direct 
toxic effect on the colonic mucosa, ap-
pears to be dose-related. Other side 
effects such as rash, pruritus, upper gas-
trointestinal complaints seem unrelated 
to dosage. In contrast with gold depos-
its in the lens, lenticular chrysiasis, de-
posits in the cornea have not been ob-
served in patients treated with oral 
gold49 
Antimalarials. Gastrointestinal and mu-
cocutaneous adverse effects are com-
pletely reversible and seem to be related 
to daily dosage of antimalarial agent. 
They appear to be unrelated to total dose 
or duration of therapy. Cumulative 
drop-out rates because of gastroin-
testinal and skin side effects are limited. 
Early reports of chloroquine (CQ)-in-
duced retinopathy emphasized cumula-
tive dosage as an important determinant 
of toxicity. " Although some recent 
studies suggest such a relation, most 
current reports fail to correlate total CQ 
and hydroxychloroquine (HCQ) dosage 
with retinopathy. This discrepancy 
may result from overestimation of the 
increase of retinopathy due to the lack of 
baseline examination (for préexistent 
macular abnormalities) or from differ-
ences in the study populations (with re-
spect to age and to daily administered 
dose). 
More agreement exists regarding daily 
drug dose: several studies have shown 
that limiting the daily dose of CQ to 250 
mg and of HCQ to 400 mg almost com-
pletely eliminates retinopathy and pre-
vents visual loss. ' Mackenzie and 
Scherbel emphasized the importance of 
relating daily drug dose to (lean) body 
weight?0,65'*"70 They suggested that 
doses up to 3.5 to 4.0 mg/kg/d of CQ and 
6.0 to 6.5 mg/kg/d of HCQ could be ad-
ministered safely. On the other hand sev-
eral case reports of patients with irrever-
sible retinopathy on the 'safe' CQ daily 
regimens have appeared. ' ' There-
fore it seems that no absolute safe dose 
regimen exists. The entirely reversible 
corneal deposits composed of antima-
larial salts, cannot be related to dosage 
or duration of therapy, and are more 
frequently observed during CQ treat-
ment than with HCQ therapy. A rela-
tion between retinopathy and kerato-
pathy has not been demonstrated. ' 
These deposits probably indicate an in-
crease of drug storage in the body. Mac-
kenzie and Scherbel advise reducing 
the dosage by half if keratopathy is de-
tected, although the value of this ap-
io 
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proach is unproven. 
In conclusion, it appears that a maximum 
daily dose of 250 mg CQ or 400 mg HCQ 
accompanied by a baseline ophthalmo-
logic examination, with follow-up once a 
year, or twice a year in patients over 65 
will suffice for early detection of revers-
ible damage before visual loss occurs. 
The benefit of annual ophthalmologic ex-
amination has been questioned, if this 
daily dose is followed. ' 
Sulfasalazine. Adverse reactions from 
sulfasalazine (SASP) in patients with in-
flammatory bowel disease (IBD) have 
been related to daily doses ranging from 
1.5 g/d to 8 g/d. Increase in the mainte-
nance dose from 2 to 4 g/d was followed 
by more frequent side effects, especially 
gastrointestinal reactions. The daily dose 
did not appear to have an effect on the 
7S 7fi 
occurrence of leukopenia; ' however, 
two cases have been described in which 
SASP-induccd pancytopenia was associ-
ated with high dosage. 
In RA patients it has been shown that 
more side effects occur on a 3 g/d regi-
men than on 1.5 g/d and that most gas-
trointestinal symptoms were dose de-
pendent. 
Penicillamine. The starting dose of d-
penicillaminc was found to influence tox-
icity. With initial doses of 125 mg/d fewer 
side effects developed than with 250 
mg/d. The rate of dosage increase also 
may be an important factor influencing 
adverse drug reactions. Although 
some researchers report that the mainte-
nance dosage of penicillamine does not 
Rf) R4 R^ 
affect the complication rate, ' ' olh-
ers report a direct correlation, ' 
particularly with respect to hemato-
logic and renal disease. 
Cytotoxic drugs. Mostly because of the 
workofRocnigketal. ' and Weinstein 
and Frost, low dose (7.5 mg to 15 mg) 
MTX, given once per week as three oral 
doses or as a single oral, intravenous, or 
intramuscular dose in arthritic and pso-
riatic patients, is a treatment widely ac-
cepted by rheumatologists and derma-
tologists. The incidence of side effects 
from MTX administered in this manner 
appears to correlate with dosage 
amount. Most side effects, such as gas-
trointestinal complaints and nausea usu-
96 99 
ally respond to dose adjustment. 
Other adverse reactions such as pneu-
monitis and hepatotoxicity do not appear 
to be dose related. 
Methotrexate therapy may induce hepa-
tocellular changes. The clinical conse-
quences of this phenomenon have not 
been fully elucidated. It is not clear 
whether these changes are related to 
weekly dose, cumulative dose or dura-
tion of the treatment.100"107 In RA pa-
tients such relations have not been 
found. " No progression in fibrosis 
score during MTX therapy was found by 
Reese et al. and Weinstein et al. 
Shergy et al. observed progression of 
the score in 23% and regression in 7%, 
of 61 RA patients with multiple liver bi-
opsies. In this retrospective study, 'mild' 
hepatic fibrosis developed in 2.9% of 210 
RA patients. Kremer et al. found a 
statistically significant worsening in he-
patic histological grade during long-term 
MTX therapy. In this prospective study, 
the development of mild fibrosis was 
common. Recently, Rau et al. re-
ported minimal periportal fibrosis in 2 
out of 10 RA patients having multiple 
liver biopsies during MTX treatment. 
Bjorkman et al, using electron micros-
copy, observed collagen deposition in 
Disse's spaces within the first year of 
treatment in all patients receiving MTX. 
The induction of cirrhosis by MTX ther-
apy has not been observed in RA pa-
l l 
»•-„f, 109,110,112,113,115-118 tients. ' ' ' 
In brief, conflicting evidence exists re-
garding the degree of hepatotoxicity 
caused by low dose MTX therapy and the 
clinical consequences of these changes. 
Therefore, the value of routine liver bi-
opsies in RA patients receiving weekly 
low dose MTX is unclear. 
Methotrexatc-induced pneumonitis gen-
erally is not considered dose re-
lated 
y i   
104,119
 I t occurs rarely in oncologic 
28. patients taking less than 20 mg/wk, and 
in an occasional RA patient. ' 
Hepatological and hematological side 
effects of azathioprine (AZA) generally 
are dose related.115'1^4'125 However, 
nausea, a common side effect in low dose 
treatment (1 to 1.25 mg/kg daily), often is 
unrelated to dosage. ' 
Leukopenia and alopecia induced by cy-
clophosphamide generally are dose rel-
ated, ' while nausea and diarrhea are 
not. ' Most long-term side effects 
from cyclophosphamide such as hemor-
rhagic cystitis, bone marrow toxicity, uri-
nary bladder fibrosis, oncogenic effects 
and gonadal dysfunction, have been as-
sociated with cumulative dose and/or du-
ration of therapy.104·124'128·130"135 
Adverse drug reactions from chlorambu-
cil treatment, in particular leukopenia, 
appear to be dose related. Renier et 
al. reported that total dosage or dura-
tion of treatment were unrelated to on-
cogenic risk. However, no leukemia has 
been described in patients given less than 
1 g chlorambucil and treated for less than 
6 months.138 
Levamisole. In a multicentre study, a do-
sage of 150 mg/wk Icvamisole caused 
more severe adverse reactions, such as 
agranulocytosis, skin rashes, mouth ul-
cers and febrile illness, than 50 mg/wk. 
The frequency ofother adverse reactions 
was comparable among the groups. 
Drug levels 
Gold. A relationship between occur-
rence of adverse effects and serum gold 
concentration was reported in 1970. 
Contrary findings were reported more 
recently.34,47,141443 In one small study a 
relationship was found between toxicity 
and red blood cell gold levels above 56 
/¿g/ml. This finding has not been con-
firmed by others.144 
In a recent report, the protein unbound, 
free gold level was thought to be related 
to toxicity; further studies are needed 
to confirm this finding. There is no cor-
relation between blood gold level and 
toxicity during oral-gold treatment.' 
43,44,47 
Antimalarials. Neither serum nor urine 
drug levels are customarily used to mon-
itor antimalarial salt treatment. How-
ever, some correlation between toxicity 
and serum levels has been reported.' 
There is conflicting evidence as to 
whether kerathopathy is related to drug 
levels.52·68·149 
Sulfasalazine. In patients with IBD and 
in healthy volunteers a direct correlation 
between serum level of the SASP metab-
olite sulfapyridine and side effects such 
as nausea, vomiting, headache and some 
hematologic effects has been described." 
75,151-155
 I n p a r l ¡ c u i a r j t h e ievei 0f frce 
sulfapyridine, the main fraction of total 
sulfapyridine in so-called slow acctyla-
tors appears to be important. A rela-
tion between this metabolite and sub-
clinical hemolysis has also been re-
ported.154,156 On the other hand the de-
velopment of methemoglobulinaemia 
may be related to the acetylated sulfa-
pyridine level, the main form of sulfa-
pyridine in fast acetylators. A similar 
relation between serum level of free or 
total sulfapyridine and toxicity possibly 
12 
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exists in RA. However, to our knowl-
edge, such an relation has not been re-
ported, nor has a relation been found 
with SASP. In single-dose studies of 
eight elderly patients, the four who 
discontinued treatment because of 
upper gastrointestinal symptoms had 
higher peak levels and larger areas under 
the curve for SASP, free sulfapyridine 
and total sulfapyridine than those who 
continued treatment. 
d-Penicillamine. No relations has been 
found between d-penicillamine levels 
and occurrence of toxicity. ' 
Methotrexate. Based on animal studies 
and small-scale clinical studies, a critical 
extracellular MTX level, and a concen-
tration threshold for every organ is said 
to exist.28,161'162 If this threshold level is 
exceeded for certain minimal time peri-
ods, damage occurs. This 'time thres-
hold' varies from a few hours for the 
kidneys to several weeks or months for 
the lungs. The extent to which the time 
threshold is exceeded, has a greater im-
pact on toxicity than the extent to which 
the plasma concentration level is ex-
ceeded. ' Edelman et al. demon-
strated that after administration of low 
dose MTX (10 mg bolus IV or IM) to RA 
patients, plasma levels may be in excess 
of 10 M for more than 24 hours, which 
is greater than the safe concentration and 
time threshold. Rheumatoid arthritis it-
self may have an additive or synergistic 
effect on MTX toxicity, resulting in 
tissue damage after low dose treatment. 
In contrast, no correlation between 
serum MTX levels and clinical response 
or toxicity was found in patients with pso-
riasis or with refractory IBD. How-
ever, Hendel et al. reported a relation 
between erythrocyte levels of MTX and 
changes in liver histology during long-
term MTX therapy of psoriasis. Thus, 
except in cases of renal impairment, sus-
pected failure of gut absorption or poor 
patient compliance, measurement of 
MTX blood levels is not clinically use-
ful.166 
Azathioprine. Serum AZA levels remain 
very low during antirheumatic treatment 
and are not useful in clinical prac-
tice, 104,127 
Cyclophosphamide. To our knowledge, 
no relation between serum cyclophos-
phamide level and toxicity has been re-
ported in RA patients. But during onco-
logical treatment, nausea coincides with 
peak plasma phosphoramide mustard 
levels.*69 
Metabolic processes 
A relation between the acetylation po-
tential by the liver enzyme N-acetyltrans-
fcrase and the occurrence of side effects 
has been shown for some drugs. For ex-
ample, among patients with IBD ' 
and healthy volunteers slow acetyl-
ators are more likely to develop adverse 
reactions from SASP than fast acetyl-
ators. Acetylatorship correlates with 
subclinical hemolysis.75,155,156 Slow 
acetylators developed more gastrointes-
tinal side effects, ' but not leukopen-
ia, hepatitis and skin rashes, during 
SASP treatment for RA. Acetylation rate 
does not influence gold or penicillamine 
toxicity.173,174 
An important factor with respect to the 
metabolism of gold and d-penicillamine 
is the oxidation of their sulfhydryl com-
ponent. In RA patients16,175,176 sulfoxi-
dation capacity was less than in 
healthy persons.78,179"180 A relation be-
tween low sulfoxidation and adverse re-
• 175 
actions during gold or d-penicilla-
mine treatment was observed by 
13 
Table 1 Association among drug levels, acetylatorship, sulfoxidation capacity and toxicity 
drug levels acetylatorship slow sulfoxidation: low 
gold IM 
oral gold 
antimalarials 
sulfasalazine 
d-pemcillamine 
methotrexate 
azathiopnne 
Abbreviations +, clear association, -, no assocation; ±, doubtful association 
Waring et al. Unlike acetylatorship, 
which can be determined from a single 
1R1 • IR'? 
scrum or urine sample the sulf-
oxidation capacity is computed from the 
proportion of sulfide and sulfoxide me-
tabolites in the urine after an oral dose of 
(750 mg) S-carboxymethyl-L-cysteine." 
179,180,103 This is a laborious procedure 
unsuitable for routine clinical use. The 
influence of such factors as disease activ-
ity and drug treatment on sulfoxidation 
status has not been excluded, as they 
have for acetylatorship.174,181,184 How-
ever, Madhok et al. recently reported 
that these factors have no influ enee on 
the sulfoxidation status. 
Age 
Questions about the safety of second-line 
treatment in the elderly are very impor-
tant. Due to the use of multiple medi-
cations, concomitant diseases, errors in 
compliance, and alterations in the drug 
pharmacokinetics adverse drug reac-
tions are more likely to occur with ad-
vanced age. A decreased tolerance for 
intramuscular gold therapy in the elderly 
was observed in earlier studies. ' A 
more recent prospective study by Kean 
et al. failed to show a statistically sig-
nificant difference in frequency and type 
of side effect in the elderly (n = 40; older 
than 60 years) compared with the 
younger patients groups (n = 101). How-
ever, serious hematologic reactions oc-
curred only in patients older than 47 
years, and all patients with nephrotic syn-
drome were older than 52 years. There-
fore more frequent monitoring of urine 
and blood appears justified in the el-
derly. The frequency of side effects with 
oral gold were almost identical in pa-
tients older and younger than 65 
years. ' ' Although some authors de-
scribe an increased risk of retinopathy in 
the elderly during CQ54 '60,61,190 and 
HCQ treatment,191 others53,55,66 did not 
find this correlation. The lack of ac-
cepted criteria for retinopathy and the 
high prevalence of the senile macular 
degeneration in the aged may account for 
these discrepant findings. Advanced age 
is not a contra-indication for antimalarial 
use, although more frequent ophthalmo-
logic examinations are advised. 
Little is known about the toxicity of SASP 
in the elderly arthritic patient. Although 
aging has little influence on the body's 
handling of SASP.193 Pullar et al.79,158 
described a higher drop-out rate from 
14 
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therapy because of upper gastrointesti­
nal symptoms in elderly patients. 
Corke and Huskisson found that age 
did not affect the occurrence of adverse 
reactions during penicillamine therapy. 
In a recent prospective study Kean et 
al. ' found significantly more skin 
rashes and marked abnormalities in the 
ability to taste in the elderly. The inci­
dence of hematologic toxicity was not 
increased, as claimed by Jaffe. 
Hepatic toxicity has been reported to be 
more common in elderly psoriatic na-
tients treated with Μ Τ χ / < 1 0 1 · 1 0 6 ' 1 9 ^ 9 8 
However, in a recent prospective study 
of MTX-treated RA patients advanced 
age did not correlate with change in he­
patic histological grade. Although no 
clear relation between age and MTX 
2Ä 
pneumonitis has been shown, the mean 
age of RA patients (n = 19Ì with this re-
action is about 60 years. ' 
Age apparently docs not influence the 
occurrence of adverse effects from 
AZA.192'199 
The effect of aging on toxicity from low-
dose cyclophosphamide treatment of the 
arthritic patient is obscure. Cyclophos-
phamide toxicity is increased in the el-
derly during cancer chemotherapy. 
Cyclophosphamide is thought to acceler-
ate the onset of menopause, particularly 
in older females. Younger women toler-
ate higher doses before permanent a-
menorrhea develops. 
RISK FACTORS RELATED TO 
IMMUNOLOGIC VARIABLES 
Immunoglobulins 
Selective immunoglobulin A (IgA) defi-
ciency has been associated with dimin-
ishing disease activity, the presence of 
the HLA-B8, B12 and B40 antigens and 
toxicity. " This deficiency may be ac-
companied by a decrease in or total ab-
sence of salivary IgA. " Serum IgA 
concentration correlates with the occur-
rence of toxic reactions to aurothioglu-
208 · · 
cose. Differences in serum IgA levels 
could not be explained by the status of 
Table 2. The influence of aging on toxicity 
gold im 
oral gold 
antimalarials 
sulfasalazine 
d-penicillamine 
methotrexate 
azathioprine 
no 
influence 
* 
* 
* 
doubtful 
influence 
* 
• 
• 
clear 
influence 
.5 
.t 
': Applies only to skin rashes and taste abnormalities 
: Applies only to hepatic toxicity 
15 
disease activity. This relation was con-
firmed by some researchers '210 and 
only partly by Ostuni et al. In the latter 
study, a statistically significant difference 
in the decrease of serum IgA concentra-
tion was observed between patients with 
and without gold toxicity after six months 
of treatment. Drug-induced (selective) 
IgA deficiency has been observed during 
treatment with parenteral gold, ' '" 
207
-
212
-
214d-penicUlamine,2fe'20¿'212·214· 
217
 anti-malarials,213 S ASP,203·218"220 
chlorambucil, fenclofenac (an 
NSAID with second-l ine fea-
tures221'222),203 and recently with Capto-
pril, (which is also thought to have 
antirheumatic properties ' ). Serum 
IgA can also become undetectable 
without administration of specific anti-
rheumatic medication. 
Harvey et al. noted a relation between 
baseline serum IgA level and hepatotox-
icity due to AZA treatment. Corke and 
Huskisson, found that baseline IgA 
level did not correlate with d-peni-
cillamine toxicity. 
210 
Jalava et al. reported that serum IgM 
levels increased in patients with side ef-
fects from aurothiomalate. This observa-
tion was not confirmed. 
Rheumatoid arthritis patients have 
higher serum IgE concentrations than 
227 2^1 
healthy volunteers. " During paren-
teral gold treatment serum IgE levels 
232 233 
rise. Davis et al. found a statistically 
significant increase in serum IgE concen-
tration in 10 of 11 patients who devel-
oped adverse reactions to aurothioma-
late. Bretza et al. observed a relation 
between serum IgE level and mucocuta-
neous and hematologic side effects from 
gold. This finding was not confirmed by 
Grcnnan and Palmer in a study of 5 
patients with gold dermatitis. 
Autoantibodies 
A relation between the presence of anti-
nuclear antibodies (ANA) before treat-
ment and the occurrence of serious side 
effects from d-penicillamine has been re-
ported,235'236 but refuted.194 '237 A 
strong relation between side effects from 
tiopronin, a d-penicillamine-like com-
pound, and gold thiosulfate and ANA 
titer has been noted. ' In the latter 
studies, a more pronounced increase in 
ANA titer during treatment was ob-
served in the toxic group than in the non-
toxic group. It is not clear whether the 
ANA have a predictive value, or if it is 
• ι 238 239 
only an epiphenomenon. 
Antigalactosyl IgG antibodies are found 
in normal human serum. Low titers of 
these antibodies are seen in immunode­
ficiency states and may be a diagnostic 
aid. By coincidence, a correlation be­
tween high titers of these antibodies and 
previous proteinuria from gold or d-
penicillamine was found. The signifi­
cance of this observation is unknown. 
Earlier studies showed that gold nephro­
pathy occurred primarily in rheumatoid 
factor-negative patients, i9 4-2 4 2-2 4 3 More 
recent studies failed to show that either 
the development of nephropathy or 
proteinuria, or drop-out rate, was in­
fluenced by the presence of rheumatoid 
factor. Corke and Huskisson found 
that patients who developed proteinuria 
during penicillamine treatment had 
lower sheep cell agglutination test titers 
prior to therapy than patients who did 
not. 
Moutsopoulos et al. ' reported that 
SSA-positive patients with RA experi­
enced more frequent side effects from 
d-penicillamine than SSA-negative pa­
tients. 
16 
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Eosinophilia 
Eosinophilia occurs in 0%232 to 43%246 
of untreated RA patients. Differences in 
definition, follow-up or constitution of 
populations studied for instance with re-
spect to steroid treatment or disease ac-
tivity, likely are responsible for this vari-
ation in percentages. Pronounced eo-
sinophilia, over 20%, has been associ-
ated with rheumatoid nodules, vasculitis, 
and high rheumatoid factor titers. 
During parenteral gold treatment eosin-
ophilia has been reported in up to 47% 
of patients. The incidence of eosino-
philia at the time of the adverse reaction 
varied between 24%250 and 78%.232 Eo-
sinophilia associated with side effects 
preceded toxicity in 70% and developed 
simultaneously in 30% of patients. 
In one study, all four patients with 
severe baseline eosinophilia developed 
severe mucocutaneous reactions after a 
brief course of gold treatment. However, 
some RA patients with préexistent mas-
sive eosinophilia do not develop unto-
ward reactions to antirheumatic medica-
tion. During oral gold treatment, eo-
sinophilia developed in 13% of pa-
tients and was observed in 30% of 
patients who experienced toxicity. 
No consistent relation between eosino-
philia and adverse drug reactions from 
other DMARDs has been found.251"254 
However, 42% of patients who devel-
2fi 25S 
oped MTX- or gold-induced pneu-
monitis had peripheral eosinophilia. 
Furthermore, hypersensitivity reactions 
to SASP,154'25*"161 d-penicillamine,262 
and AZA, may be accompanied by 
eosinophilia. In view of above it appears 
that eosinophilia in itself cannot adequa-
tely predict an adverse drug reaction. 
However, simultaneous occurrence of 
eosinophilia and adverse effects, espe-
cially mucocutaneous and pulmonary re-
actions, strongly suggests a drug re-
action. 
MISCELLANEOUS RISK FACTORS 
Combined DMARD therapy 
In the management of several malignant 
diseases, combined 'aggressive' chemo-
therapy is commonly used. Combining 
DMARDs has also been advocated for 
some cases of intractable RA. The conse-
quences of combining DMARDs with 
regard to toxicity are reviewed below. 
Increased toxicity has been reported 
when intramuscular gold and hydroxy-
chloroquine are adminis tered to-
gether. A rapid decrement in leuco-
cyte count during combined AZA and 
SASP treatment was observed in three 
patients with adult Still's disease.265 
Using information from an open study, 
Taggart et al, found that a combina-
tion of SASP (2 g/d) and d-penicillamine 
(500 g/d) was more potent than SASP 
alone, but caused more side effects. Re-
cently, Farr et al. found no increase of 
adverse reactions in SASP-lreated pa-
tients (1.5 to 3 g/d) when d-penicillamine 
(125 to 1,000 mg/d) or intramuscular 
gold (50 mg/week) was added, compared 
with penicillamine or gold monotherapy. 
ΟΛΟ 'T?Q f'flì 
Based on animal ' and in vitro 
studies, cyclophosphamide should be ad-
ministered with caution to patients re-
ceiving antimalarials. Clements and 
Davis stated in their review article that 
concurrent or sequential use of more 
than one cytotoxic drug may increase the 
risk of interstitial lung fibrosis. Several 
severe adverse reactions, including the 
probable induction of malignancies, have 
17 
Table 3 The influence of previous therapy on the development of adverse drug reactions 
previous therapy 
gold im oral gold antima-
larials 
d-pem- azathio- levamisole chloram-
cillamme pnne bucil 
gold im 
sulfasalazine 
d-penicillamine 
cyclophosphamide 
Abbreviations -, no influence, +, some influence 
been reported during combination ther-
apy with HCQ, AZA and cyclophospha-
mide. However, McCarty and Car-
rera encountered no serious compli-
cations when 17 patients with intractable, 
mostly nodular, often vasculitic RA were 
treated with the same combination of 
drugs introduced sequentially. 
Although Seideman and Lindstrom 
recently reported that plasma penicilla-
mine concentrations increase by 34% du-
ring concomitant CQ treatment, toxicity 
was unaltered or even diminished during 
combination therapy of d-penicillaminc 
and (hydroxy)chloroquine compared 
with d-penicillamine alone. " Com-
binations of MTX and HCQ,98 of MTX 
277 
and parenteral gold, of AZA and 
gold,578 of MTX and AZA279 and of 
HCQ, cyclophosphamide and MTX 
did not influence toxicity. 
Sequence of DMARDs 
Although some earlier studies suggested 
that previous gold treatment increases 
d-penicillamine toxicity, especially renal 
and hematologic side effects, these dif-
ferences in toxicity ' ' ' and drop-
out rate were not observed in more 
recent studies. Toxicity was not influ-
enced by the sequence of drug adminis-
tration or by the length of drug-free in-
terval. Previous second-line therapy 
with sodium aurothiomalate, d-penicill-
amine, levamisole, antimalarials, AZA, 
or oral gold did not influence toxicity 
from SASP treatment.284 
Carson et al. found that pulmonary 
toxicity from MTX was not influenced by 
the number and types of previous 
DMARDs used. Kremer et al. found 
no correlation between previous total 
gold dose and hepatocellular changes 
during long-term MTX treatment. 
Shaunak et al. described four patients 
who developed liver cell necrosis from 
cyclophosphamide after earlier azathio-
prine treatment. The authors suggested 
that earlier administration of AZA might 
increase the risk of liver toxicity from 
cyclophosphamide. The risk of malig-
nancy induction with cyclophosphamide 
increases with previous cytotoxic ther-
apy·138 
Previous toxicity from other DMARDs 
Several reports ' " state that previ-
ous gold toxicity is a risk factor for d-
18 
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penicillamine toxicity, especially if the 
drug-free interval between DMARDs is 
less than 6 months. However, other stud-
• 18,80,239,276,290,291 . » r »i.-
ies ' ' ' u.«v,¿" ¿0 not confirm this 
findings. Based on the results of their 
small study, Tumiati et al. claim that 
the use of oral gold is justified in patients 
with previous mucocutaneous reactions 
from gold IM. Bandilla and Missler 
offer the opinion that it is probably safe 
to administer oral gold to patients who 
developed side effects from other sec-
ond-line drugs (gold IM, d-penici-
llamine, CQ), except for severe skin 
rashes from parenteral gold. Recently, it 
was shown that RA patients with side 
effects from parenteral gold and/or d-
penicillamine (n = 29) tolerated oral 
gold.294 Thus, previous DMARD toxic-
ity docs not appear to influence subse-
quent toxicity from other second-line 
agents. There is one possible exception 
to this generalization; Bliddal et al. 5 , 2 % 
reported leucocyte depression during 
SASP therapy in three patients who had 
similar reactions to previous gold treat-
ment. 
Smoking 
The potential effect of smoking on the 
development of retinopathy during niva-
quine treatment in patients with sub-
acute lupus erythematosus was de-
scribed in one study. Kay et al. ob-
served that skin rash from parenteral 
gold was more common in smokers than 
in nonsmokers. This association was not 
confirmed by others. · ' In one 
trial smokers developed adverse reac-
tions about twice as fast as nonsmokers. 
While smoking increases erythrocyte 
gold levels,^**9 '300 there is no correla-
tion between such levels and the frequen-
cy of side effects. The drop-out rate from 
chrysotherapy does not appear to be in-
fluenced by smoking. Based on a few 
case reports Searles suggested that smo-
king, especially in older men with a pré-
existent lung disease, constituted a risk 
factor for the development of MTX-in-
duced pneumonitis. Bell et al. 
reported that preexisting pulmonary ab-
normalities may predispose to MTX lung 
toxicity in RA patients. However, Carson 
et al. did not substantiate these find-
ings. 
Other 
Although it is likely to assume an addi-
tional effect of alcohol on MTX-induced 
hepatotoxicity, ' ' some authors 
report the absence of such an effect." 
100,101,105 
Diabetes and obesity, especially if pres-
ent simultaneously, appear to increase 
the risk of MTX-induced hepatotoxic-
^97,101,110,112,198 ^ ^
 c o n n i c t ¡ n g 
opinions exist. ' 
CONCLUSION 
There is little agreement in the literature 
regarding risk factors for DMARD 
toxicity. Factors responsible for this dis-
agreement may include the retrospective 
design of most studies, the broad varia-
tion in side effects encountered, and the 
relatively small size of, and differences 
in, patient groups studied. Furthermore, 
most studies lack adequate criteria for 
ascertaining adverse drug reactions. 
Despite these shortcomings some find-
ings of interest emerge from this litera-
ture review. Doses of CQ and HCQ ex-
ceeding 3.5 to 4.0 mg/kg/d and 6.0 to 6.5 
19 
mg/kg/d, respectively, appear to be the 
principal risk for developing retinopathy. 
Low sulfoxidation capacity, smoking, 
IgA deficiency, eosinophilia and HLA-
DR3 predispose to parenteral gold tox­
icity. Serum gold level does not seem to 
be of influence. Sulfoxidation status, 
starting dose, HLA-DR3 phenotype, and 
age arc factors influencing the develop­
ment of side effects from d-pcnicil-
lamine. Previous chrysotherapy or gold 
toxicity probably do not affect the risk of 
d-penicillamine toxicity. Acetylatorship, 
age and the dose appear to influence 
SASP toxicity, especially for minor side 
effects. Most of the common side effects 
from MTX respond to dose adjustment. 
Previous AZA treatment may increase 
the risk of liver cell necrosis from cyclo­
phosphamide. The sensitivity and speci­
ficity of these risk factors in predicting 
the occurrence of adverse effects from a 
given patient are low; therefore, routine 
clinical and laboratory monitoring is nec­
essary. If a risk index, combining risk 
factors and having predictive value could 
be developed, then, interventions such as 
switching DMARDs, adjustment of dose 
or regimen, and selective monitoring 
would improve the risk-benefit ratio of 
DMARD therapy. 
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Hemolysis during sulfasalazine (SASP) therapy in patients with Inflammatory Bowel Disease (IBD) is a well known feature. ' In this condition its occurrence 
is related to dosage, sulfapyridine level and acetylatorship. No studies reporting 
hemolysis in Rheumatoid Arthritis (RA) patients, generally treated with a lower dose 
SASP (2 to 3 gram per day), have been published. However, Farr et al. reported a 
slight rise in hemoglobin level (Hb) in only 4 out of 19 patients with clinical and 
laboratory improvement during SASP therapy for RA. In the study of Grindulis et 
al. a significantly lower Hb level was observed at week 24 in patients taking SASP 
compared with patients taking d-penicillamine, despite a comparable improvement 
in ESR and CRP. In this last study a significant increase in MCV in RA patients taking 
SASP was reported. As an explanation hemolysis was suggested, although not estab­
lished. Furthermore, Hopkinson et al. recently reported macrocytosis in 20.8% of 
inflammatory arthritis patients treated with SASP. In less than 35% of these patients 
with macrocytosis low red cell folate levels were found. For the remaining proportion 
no explanation for the macrocytosis was mentioned. We reviewed the data of our 
double blind study of hydroxychloroquine versus sulfasalazine in the treatment of 
rheumatoid arthritis, with special attention to the occurrence of hemolysis. Further­
more, the relationship between Hb and disease activity (DA) in both treatment groups 
was studied. 
MATERIALS AND METHODS 
Patients. Sixty patients with definite or 
classical RA according to the ARA cri­
teria entered the 48 weeks randomized 
clinical study. All had active disease and 
no patient had previously been treated 
with either second-line drugs or cortico­
steroids. 
Medication. Hydroxychloroquine (HQ) 
treatment consisted of 200 mg b.i.d. dur­
ing 24 weeks, after that of 200 mg daily. 
Sulfasalazine therapy comprised an ini­
tial dose of 500 mg daily (enteric coated), 
increased by 500 mg every four days to a 
maximum daily dose of 2000 mg. 
Assessments. Various clinical DA vari­
ables, including duration of early morn­
ing stiffness and Ritchie articular index, 
were recorded monthly. Laboratory 
tests, including Westergren erythrocyte 
sedimentation rate (ESR), white blood 
cell count and differential, hemoglobin 
(Hb), mean corpuscular volume (MCV), 
platelet count, LDH and C-reactive pro­
tein (CRP) were done at the same time 
as the clinical assessments. Measure­
ments of serum folate (RIA) and vitamin 
В12 levels were carried out at weeks 0, 
24, and 48. Reticulocyte counts were 
done at weeks 0, 4, 12, 24, 36, and 48. 
After centrifugation, plasma and serum 
samples collected at every visit were 
stored at -20oC pending analysis. After 
completion of the trial scrum haptoglo­
bin levels were determined in the sam­
ples of week 0,4,8,12,16,24,36, and 48 
using commercially available immuno­
diffusion plates (NOR-Partigen-Hapto-
globin, Behring). For statistical analysis, 
haptoglobin levels below the detection 
threshold (0.38 g/1) were arbitrary cho­
sen to be 0.29 g/1. Serum hemopexin lev­
els were measured also using the immu­
nodiffusion technique (NOR-Partigen, 
Behring). The concentrations of sulfa-
35 
pyridine and its metabolite N4-acetyl-
sulfapyridinc in the plasma samples of 
the SASP treated patients were mea-
sured by means of High Performance 
Liquid Chromatography. Acetylator sta-
tus was determined by the percentage of 
acetylated sulfapyridine: acetylated sul-
fapyridine level divided by sulfapyridine 
plus acetylated sulfapyridine level (over 
42.5% fast; under 42.5% poor). 
Statistics. Five commonly used DA vari-
ables (clinical: Ritchie articular index, 
early morning stiffness; laboratory: ESR, 
CRP, platelet count) were transformed 
to symmetrical distributions (power 
transformation), followed by transfor-
mation to z-scores (standard deviation 
scores). By adding up these z-scores, an 
index reflecting DA called 'activity index' 
not including Hb, was computed. This 
index was found to have an acceptable 
internal consistency and reliability 
(Cronbach's alpha = 0.73).8 
RESULTS 
Initially, 60 patients participated in the 
study. At the start of the study no statis-
tical differences in either clinical or lab-
oratory parameters were found between 
the two treatment groups. 
The minimal duration of follow-up to 
compute intra-individual correlations 
between the various variables, was set at 
four months. Nine patients were with-
drawn from the study within four months. 
In one patient infectious mononucleosis 
was diagnosed. As hemolysis has been 
found to occur in this disease, this pa-
tient was also left out, leaving 28 patients 
in the HQ group and 22 patients in the 
SASP group for statistical analysis. 
Hemolysis. In order to detect hemolysis, 
MCV, reticulocyte count, and LDH were 
reviewed from the original study and 
haptoglobin levels determined in the 
serum samples stored. Since we only had 
frozen serum at our disposal, it was not 
possible to determine blood methemo-
globin or to examine for Heinz bodies. In 
the SASP group an increase in MCV was 
observed (fig 1). However, macrocytosis 
(MCV > 100 fl) occurred in only one pa-
tient of the SASP group. 
No statistically significant increase in re-
ticulocyte count or LDH occurred in ei-
ther group. At the start of the study hap-
toglobin levels were raised in both treat-
ment groups, followed by a significant 
decrease during therapy. The decrease 
in haptoglobin was more pronounced in 
the SASP group and only in this group 
the haptoglobin level became undetec-
table ( < 0.38 g/1) in 5 patients. In these 
patients an early fall in serum haptoglo-
bin levels was observed. After discon-
tinuing SASP treatment following com-
pletion of the 48 week study in two of 
these five patients the haptoglobin level 
normalized. The levels remained very 
low in the three patients who continued 
taking SASP (fig 2). 
In three of the five patients with unde-
tectable haptoglobin subnormal serum 
hemopexin levels were found. An in-
crease in LDH was observed in three 
patients and reticulocytosis in one pa-
tient. Macrocytosis was not found among 
these 5 patients. A slight decrease in 
serum folic acid was found in only one of 
these five patients. No vitamin B12 defi-
ciencies or abnormal values for alkaline 
phosphatase, gamma-GT or transamina-
ses developed. In all these five patients a 
decrease in Hb occurred although the 
Hb did not fall below 99 g/1. Irregular 
antibodies to erythrocytes (indirect 
Coombs) were not found. No significant 
differences in serum levels of sulfapyri-
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dine or acetylatcd sulfapyridine were 
found between these five and the other 
SASP treated patients. Neither were dif­
ferences in acetylator status: 40% slow 
acetylators among the patients with 
undetectable haptoglobin versus 4 1 % 
among the others. 
Relationship between Hb and DA. To 
study the relationship between Hb and 
DA in the individual patient, and the 
influence of the kind of drug therapy on 
this relationship, Pearson's correlation 
coefficients between Hb and the 'activity 
index1 were calculated within each pa­
tient (n = 50). The mean value of these 
individual correlation coefficients 
reached -0.39 in the HQ and -0.08 in the 
patients treated with SASP. This differ­
ence reached statistical significance (t-
test, ρ < 0.015). In fig 3 these individual 
correlation coefficients are plotted 
against the minimal haptoglobin level 
(after square root transformation) 
reached during the trial. A correlation 
between the coefficients and the minimal 
haptoglobin values is shown (r = -0.51; 
ρ < 0.0001), revealing haptoglobin as a 
confounding factor in the relationship 
between Hb and DA. Analysis of covar-
iance confirmed the influence of the kind 
of therapy on the correlation between Hb 
and the 'activity index.' Furthermore, 
after correction for the minimal hapto­
globin level the influence of therapy dis­
appeared. 
DISCUSSION 
A relative lack of increase of Hb was 
observed in the SASP treated patients, 
despite diminishing disease activity. This 
phenomenon can possibly be explained 
by hemolysis, which is, as mentioned pre­
viously, often observed in patients with 
inflammatory bowel disease during sul­
fasalazine treatment. We studied the oc­
currence of hemolysis in both SASP- and 
HQ-treated patients. Curiously, no dif­
ferences in LDH or reticulocyte count 
were found between both treatment 
groups. At the start of the study hapto­
globin levels were raised in both groups 
as part of the acute phase response, fol­
lowed by a significant decrease in both 
groups. However, in the SASP group the 
fall of the haptoglobin level was more 
pronounced. This can in part be ex­
plained by a faster and greater fall in 
disease activity in this treatment group. 
Only in five SASP treated patients did 
the haptoglobin level become undetect­
able. Impaired liver function causing a 
decrease in haptoglobin synthesis was 
unlikely because of the absence of in­
creased serum alkaline phosphatase and 
transaminases. Vitamin B12 deficiency 
could not be held responsible for the fall 
in haptoglobin level, either. It has been 
shown by Marchand et al. that unde­
tectable haptoglobin levels are indicative 
of hemolysis with a sensitivity of 83% and 
a specificity of 96%. With depletion of 
haptoglobin some hemoglobin is oxi­
dized to methemoglobin. The oxidized 
hacm moiety, haemin, is dissociated from 
methemoglobin and avidly bound to he-
mopexin, a glycoprotein of the beta-glo­
bulin class. This haemin-hemopexin 
complex is cleared by the liver. In three 
of the patients with undetectable hapto­
globin subnormal serum levels of hemo-
pexin were found. An alternative expla­
nation for the increase in MCV and the 
lack of increase of the Hb level in the 
SASP treated patients could be folate 
deficiency. It is known that SASP has 
certain properties of an antifolate drug.-
11,12,13,14,15
 H o w e v e r j t h e s e ami-folate 
mechanisms appear to be dose-depend-
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Figure 3. Influence of haptoglobin on the correlation between Hb and DA 
(r = -0.51, ρ < 0.0001, Pearson's correlation coefficient) 
ent and of major interest only in patients 
treated with more than 2000 mg daily. In 
our study, there was no clear indication 
of folate deficiency as a cause of the fea­
tures mentioned above. 
Thus, our data are highly suggestive of 
hemolysis in the SASP treated RA pa­
tients. However, further studies are 
needed to confirm these findings. It was 
striking that no differences in sulfapyri-
dine levels or acetylatorship were found 
between the five patients with undetec­
table haptoglobin and the other SASP 
treated patients, in contrast to what has 
been described in IBD patients. How­
ever, this may be due to the small num­
bers (type II error). It is furthermore 
interesting that the mean level of serum 
sulfapyridine in our patients with hapto­
globin levels below 0.8 g/l was far below 
the levels described by Van Hecs et al. 
in IBD patients with similar haptoglobin 
values (15.79 ^g/ml as against 53.80 
¿ig/ml, ρ < 0.002, t-test, two-tailed). This 
phenomenon is probably an indication of 
a greater susceptibility to hemolysis in 
RA compared to IBD patients. 
In order to study the effect of hemolysis 
on Hb as a disease activity parameter the 
correlation between Hb and the newly 
computed index of DA called 'activity 
index,' was calculated for each patient. 
The mean values of these individual cor­
relation coefficients for each treatment 
group differed significantly, indicating 
that the relationship between Hb and 
DA is influenced by kind of treatment. 
After exclusion of the 5 patients with 
undetectable haptoglobin levels, the dif­
ference between the mean values of the 
correlation coefficients and the increase 
in MCV among the SASP-lreated pa­
tients remained, indicating that hemoly­
sis is probably not restricted to the pa­
tients with undetectable haptoglobin. 
The correlation between these coeffi­
cients and the minimal haptoglobin val­
ues reveals haptoglobin (hemolysis) as a 
confounding factor in the relationship 
between Hb and DA. 
Conclusion. Drug-induced subclinical 
hemolysis should seriously be considered 
as a cause of the relative lack of increase 
of Hb in arthritic patients, successfully 
39 
treated with relatively low dose sulfa- makes Hb, a commonly used disease ac-
salazine. The clinical significance of the tivity parameter in RA, unreliable for the 
induced hemolysis is limited. However, it evaluation of SASP treatment. 
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Azathioprine has been shown to be an effective cytotoxic drug for the management of rheumatoid arthritis. Commonly known side effects include bone marrow 
suppression, hepatotoxicity, and infection. The оссштепсе of skin reactions is a rather 
rare (0-5%) complication. To our knowledge, only two patients developing urticaria 
due to azathioprine have been described in the literature. ' 
We describe here a 31-year-old patient with a severe generalized toxicodermatitis 
with urticaria accompanied by 'flu-like' symptoms during azathioprine treatment and 
report some characteristics of azathioprine-induced cutaneous reactions described 
in the literature. 
CASE REPORT 
The patient was a 31-year-old woman, 
who developed an erosive seropositive 
rheumatoid arthritis after the birth of her 
third child, 7 years ago. Initial treatment 
consisted of nonsteroidal antiphlogistic 
drugs. Subsequently the following dis­
ease modifying antirheumatic drugs 
(DMARDs) were added: hydroxychloro­
quine (stopped because of lack of effi­
cacy); aurothioglucose (discontinued be­
cause of leukopenia after one year of 
treatment, spontaneously recovered); 
sulfasalazine (immediately stopped be­
cause of severe nausea and vertigo); oral 
gold (auranofm) (discontinued because 
of loose stools, dermatitis and gastro­
intestinal complaints). 
To relief the patient's complaints caused 
by considerable disease activity, low-dose 
corticosteroids (10 mg daily) were pre­
scribed, resulting in some abatement of 
disease activity. Azathioprine 50 mgb.i.d. 
was added 6 months later and the corti­
costeroids were successively reduced. At 
first, this drug was well tolerated. How­
ever, no dramatic amelioration was ob­
served. After 5 months of azathioprine 
therapy the patient developed a slight 
rash, restricted to the sun-exposed areas. 
Two months after, she developed a severe 
generalized itchy dermatitis accompani­
ed by myalgia, fever, gastralgia, nausea 
and diarrhea. She could not recall any 
previous contact with children (or peo­
ple) suffering from (possible) infectious 
diseases. The medication at the time the 
skin lesions broke out consisted of aza­
thioprine 50 mg b.i.d., naproxen 250 mg 
t.i.d., prednisone 7.5 mg daily, fcrrofu-
merate 200 mg daily, calcium lactoglu-
conate 5.23 g and Calciumcarbonate 0.80 
g daily, corresponding with 1000 mg ion­
ized calcium, and sporadically parace­
tamol and vitamin C. 
Because of the severe pruritus the gen­
eral practitioner prescribed clemastine 1 
mg b.i.d. Clinical examination of the skin 
revealed a pronounced urticarial erup­
tion on the trunk, and to a lesser degree 
on the extremities. Dermographing was 
strongly positive. Furthermore, Chemosis 
was clearly present. Examination of the 
joints still showed active disease of both 
hands, wrists, the right elbow and both 
knees. Laboratory investigation showed 
an increased erythrocyte sedimentation 
rate (ESR): 76 mm in the 1st h, which 
used to be about 40 mm; a slightly ele­
vated ALAT: 37 U/l; alkaline phospha­
tase: 62 U/1; LDH: 293 U/l; hemoglobin: 
8.1 mmol/1; white blood count: 7.9 χ 109/1, 
normal differential; platelet count: 331 χ 
10 /1; very low serum IgA: 0.13 g/1; in­
creased IgG: 22.5 g/1 and IgM: 1.80 g/1; 
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Rose-Waaler: 320 lU; latex reaction: 400 
IU; C3: 1719 mg/l; C4: 269 mg/l; Clq 
binding assay: 32%; antinuclear antibod­
ies: positive, homogen pattern. HLA-typ-
ing of the B-locus and D-locus: B5, B40, 
Bw4, Bw6, Bw60, DR2, DR4 and DRw53. 
Histopathological examination of a skin 
biopsy taken from an urticarial lesion on 
the right thigh revealed a normal epider­
mis. The superficial vascular plexus was 
surrounded by a dense inflammatory in­
filtrate consisting predominantly of neu­
trophils with some mononuclear cells and 
eosinophils. Many of the neutrophils 
showed fragmentation of the nuclei. The 
capillaries showed pronounced swelling 
of the endothelial cells, with deposition of 
fibrinoid material and minimal erythro-
diapcdesis. These findings are compati­
ble with leukocytoclastic vasculitis. 
All medication except naproxen, pred­
nisone and clemastine were stopped. 
One and a half weeks after, the dermatitis 
and the gastrointestinal complaints had 
completely vanished. In the next few 
months the patient's previous medication 
(except for the azathioprinc) was reintro­
duced, without untoward reactions. Aza­
thioprine was not rechallenged as this 
drug hardly showed any beneficial effect 
on the patient's disease activity. More­
over, challenge may be dangerous be­
cause it can induce shock. ' 
COMMENT 
Hypersensitivity reactions, occurring 
about 2 weeks after the prescription of 
azalhioprine, with varying combinations 
of symptoms such as fever, gastrointesti­
nal complaints, arthralgia, myalgia, hypo­
tension, rash and leukocytosis are well 
documented in the literature. We found 
Table I Clinical characteristics of 17 patients with azathiopnnc-induced cutaneous drug reaction 
described in the literature 
Skin lesion 
Fine maculopapular rash 
Erythema 
Eczema 
Blisters 
Urticaria 
Purpura, petechia 
Fever 
Gastrointestinal 
Nausea 
Vomiting 
Gastralgia 
Diarrhea 
Headache 
Dyspnoe 
Locomotion 
Myalgia 
Arthralgia 
17 
б 
8 
2 
2 
2 
1 
* Present in the patient described 
References 1,3-3,7-13 
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Generalized urticarial eruption during azathiopnne 
17 reports of cutaneous reactions due to 
azathioprine treatment. In only 3 cases 
rheumatoid arthritis patients were af­
fected. The development of urticaria was 
described in only 2 patients. Symptoms 
accompanying these skin-side adverse re­
actions are listed in Table I. 
Histopathological findings were de­
scribed for 4 patients and were compati­
ble with leukocytoclastic vasculitis in one 
case, with aspecific inflammation in 2 and 
with suppurative inflammation in one. 
Laboratory assessment revealed leuko­
cytosis in 2 patients, a raised ESR in 2 and 
a rise in scrum transaminase levels in one. 
In all but one, the symptoms emerged in 
a few days, or up to a few weeks (mean: 
13 6 days; range: 3-28 days) after aza­
thioprine was prescribed. It is quite re­
markable that in all 9 patients who were 
rechallenged, the symptoms recurred. A 
possible explanation could be that these 
patients with a positive provocation test 
were selected for publication. 
The patient we describe developed a skin 
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rash about 6 months after starting aza­
thioprine medication, with symptoms 
which are all listed in Table I. Clinically, 
the lesions were urticarial. Histopatho-
logically, a leukocytoclastic vasculitis was 
found. Thus, this eruption may be classi­
fied as an drug-induced urticarial vascu­
litis. Although the epidemiological in­
fectious history given is negative, an alter­
native explanation for the patients symp­
toms, which ought to be considered, is a 
viral infection, especially as the patient 
used azathioprine and corticosteroids. 
Of further interest is that our patient, who 
developed several adverse reactions to 
four subsequent ly a d m i n i s t e r e d 
DMARDs, had very low serum IgA lev­
els, both before and during azathioprine 
treatment. Low IgA levels, have been as­
sociated with the development of side 
effects of DMARDs. 1 4 , 1 5 This feature 
probably reflects an increased suscepti­
bility to untoward drug reactions in our 
patient. 
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ABSTRACT 
A 56 year old woman with rheumatoid arthritis developed relapsing thrombocyto­
penia during successive treatments with aurothioglucose, sulfasalazine and hydroxy­
chloroquine. The presence of IgM or IgG antibodies or immune complexes reactive 
with autologous platelets could not be shown. Relapsing thrombocytopenia may 
indicate a genetically determined HLA-DR3 and B8 aberrant immunological re­
sponse to stimuli such as certain second-line drugs. 
Treatment with second-line antirheu­matic drugs often produces side ef­
fects. In this report we describe an ex­
ceptional patient with rheumatoid ar­
thritis who developed isolated thrombo­
cytopenia during successive treatments 
with aurothioglucose, sulfasalazine and 
hydroxychloroquine. Although throm­
bocytopenia is a common side effect of 
parenteral gold, it is very rare during 
treatment with sulfasalazine and has 
only once been reported to be caused by 
hydroxychloroquine. 
CASE REPORT 
A 56 year old woman had had seroposi­
tive rheumatoid arthritis since January 
1986. Initial treatment consisted of non­
steroidal anti-inflammatory drugs. Be­
cause of persistent disease activity, par­
enteral gold (aurothioglucose 50 mg 
weekly) was added. After five months 
this effective treatment had to be discon­
tinued because of dermatitis and pro­
teinuria. Parenteral gold treatment was 
reinstated after one year in a very low 
dose (5 mg monthly). During the four 
months that this low dose treatment was 
given, the patient reported neither im­
provement nor side effects. 
In August 1988 the patient visited our 
hospital for the first time. Physical exam­
ination showed active polyarthritis of the 
hands, wrists, elbows and forefeet. Lab­
oratory investigations showed an in­
creased erythrocyte sedimentation rate 
(ESR) of 89 mm in the first hour; a 
hemoglobin of 6.1 mmol/1 (98 g/1); a 
white cell count of 5.7 χ 10 /1 with a 
normal differential; a platelet count of 85 
χ 10 /1; no antinuclear antibodies. A 
Rose-Waaler test gave a result of 320IU, 
and the latex reaction was 50 IU. There 
was no proteinuria. HLA typing was 
done and showed the presence of the 
HLA-B8 and HLA-DR3 antigens. Be­
cause of the thrombocytopenia the 
platelet count was repeated after a few 
days; it then amounted to 150 χ 109/1. A 
month later the platelet count was 186 χ 
10 /1 and parenteral gold was resumed, 
now in the usual dose of 50 mg. After a 
single intramuscular injection severe 
thrombocytopenia with a platelet count 
of 5 χ 10 /1 occurred. Physical examina­
tion yielded normal results, in particular, 
no signs of bleeding or enlargement of 
the spleen were found. All drug treat­
ment, including parenteral gold, na­
proxen, and paracetamol, except tcma-
zepam, was discontinued. Treatment 
consisted of infusion of 6 units of throm-
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bocyte concentrate and prednisone 40 
mg daily. The patient's previous drugs, 
except aurothioglucose, were subse­
quently reinstated. A fast recovery of the 
platelet count occurred (fig 1) and the 
prednisone was tapered off. After dis­
continuation of the corticosteroids a 
. flare-up of the disease occurred and sul­
fasalazine was prescribed. The patient 
responded very well to this, but again the 
platelet count dropped to 35 χ 10 plate­
lets/1. Physical examination showed no 
signs of bleeding, but there was a slight 
erythema on the back and mild arthritis 
of some fìnger joints and the right knee. 
Laboratory tests showed an ESR of 57 
mm in the first hour; a hemoglobin con-
centration of 7.4 mmol/l (119 g/1); a white 
cell count of 5.2 χ 10 /1, with a normal 
differential; a C3 of 1726 mg/l; C4: 275 
mg/1; Clq binding assay of 5%; circulat­
ing immune complexes containing IgM 
and small amounts of IgG. Immune com­
plexes containing IgA were not found; 
IgM was 1.09 g/1; IgG was 11.3 g/1; and 
IgA was slightly increased to 2.63 g/1. 
Bone marrow examination showed 
megakaryocytosis and no signs of in­
creased intramedullary activity of the 
mononuclear phagocyte system. Sul­
fasalazine was stopped and spontaneous 
recovery of the thrombocyte count was 
noticed. The patient sustained another 
flare-up of the disease and hydroxy­
chloroquine treatment was started. 
After two and a half months the throm­
bocyte count fell again to 70 χ 10 plate­
lets/1. The thrombocyte count rose to 
nearly normal values within two weeks 
after discontinuing the hydroxychloro­
quine. Low dose corticosteroids were 
given because of persistent disease activ­
ity. Since then the patient has had a nor­
mal thrombocyte count. 
Serum samples obtained in October, 
November, and twice in February were 
fractionated by isokinetic sucrose gradi­
ent centrifugation as described by 
Faaber et al. Undiluted scrum fractions 
were tested for IgM and IgG reactivity in 
an enzyme linked immunosorbent assay 
(ELISA) as described by Sintnicolaas et 
al. The reactivity of the patient's serum 
fractions with autologous platelets indi­
cates that no IgG or IgM autoreactive 
platelet antibodies were present. The re­
activity patterns of patient and control 
sera were identical. No auto- or allorcac-
tive IgM or IgG immune complexes were 
present, which could be concluded from 
the data obtained with the 'pellet or 
bottom' fractions in the ELISA. IgG al-
loreactivity was clearly shown in the 
serum sample obtained in November 
four weeks after the platelet transfusion. 
The serum sample obtained four months 
later showed hardly any IgG alloreacti-
vity. 
DISCUSSION 
Thrombocytopenia as a result of drug 
treatment is a rather common feature, 
occurring in 1-3% of patients treated 
with parenteral gold. Two different 
types of thrombocytopenia have been 
distinguished : the 'toxic' type and the 
more common 'immune mediated' type. 
With respect to the latter, a strong cor­
relation with the presence of the HLA-
B8 and HLA-DR3 antigens has been 
found. 7 1 1 
The fact that we could not show the pres­
ence of autoreactive antibodies or im­
mune complexes in the patient reported, 
not even in the serum sample obtained 
during severe thrombocytopenia, does 
not necessarily mean that autoreactive 
antibodies or immune complexes could 
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Figure 1. Hematological indices and treatment over time 
not have been responsible for the severe 
thrombocytopenia. In retrospect, the 
thrombocytopenia noted in our patient 
at the initial visit might have been caused 
by the low dose gold given before refer-
ral to our hospital. In about 30% of pa-
tients with drug-induced thrombocyto-
penia antibodies reactive with autolo-
gous thrombocytes can not be found in 
in vitro tests. Sometimes the binding of 
antibodies or immune complexes to pla-
telets can be observed only when the 
suspected drug - or one of its metabolites 
- is added.1 We screened the sera 
without additions. An alternative expla-
nation for why autoreactivity was not de-
tected may be that autoreactive antibo-
dies might have been of low titres, ad-
sorbed to the platelets, and cleared from 
the blood. Because of the high sensitivity 
ofthe ELISA we reject lack of sensitivity 
as an explanation; we also reject the di-
lution introduced by the fractionation 
(less than 1/10) as an explanation, for the 
signals of unfractionated sera did not 
exceed the signals of the fractionated 
sera (data not shown). 
The alloreactivity found in the serum 
sample taken in November can most 
likely be explained as being due to a 
secondary response provoked by the 
transfusion, because the patient had 
been pregnant in the past. 
To our knowledge, an isolated thrombo-
cytopenia resulting from treatment with 
sulfasalazine has not been described ei-
ther in patients with inflammatory bowel 
disease, or in rheumatoid arthritis. Only 
cases of thrombocytopenia associated 
with concomitant leucopenia, ' hypo-
gammaglobulinaemia, and erythroid 
aplasia have been reported. 
Antimalarial drugs such as quinine and 
quinidine are notorious for inducing 
thrombocytopenia. Chloroquine also 
has been reported to possess such prop-
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erties. Although hydroxychloroquine 
is regularly prescribed for patients with 
rheumatoid arthritis, and in large quan­
tities, occurrence of thrombocytopenia 
induced by this drug has been reported 
only once. 
It is not known whether previous throm­
bocytopenia during chrysotherapy in­
creases the risk of recurrence of a fall in 
platelet count during subsequent treat­
ment with sulfasalazine or hydroxy­
chloroquine, as has been suggested by 
Bliddal et al. 2 3 , 2 4 The relapsing throm­
bocytopenia, however, may indicate a 
genetically determined HLA-B8 and 
HLA-DR3 aberrant immunological re­
sponse to stimuli such as certain second-
line drugs. 
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The most common side-effect of parenteral gold therapy in rheumatoid arthritis is cutaneous eruptions. At this university hospital, consecutive patients with re­
cently diagnosed rheumatoid arthritis who had not previously been treated with 
second-line antirheumatic drugs were asked to participate in a long-term prospective 
open study in which treatment by different rheumatologists was monitored by a 
research nurse. Parenteral gold was started in 47 of the 148 patients. During chryso­
therapy 14 patients had a dermatitis severe enough for the dose to be reduced or for 
gold to be discontinued. Two patients had dyshidrotic eczema, 1 had papular prurigo, 
and 1 had mycosis; a close resemblance to contact dermatitis was noticed in 3 patients; 
and in the other 7 'gold dermatitis' was diagnosed by exclusion (table I). 
The patients with a contact-dermatitis-like rash were all female, and 2 had previously 
been sensitized to nickel; the time to recovery after discontinuation of chrysotherapy 
was shorter in these patients than in those with gold dermatitis. One patient who had 
a reaction compatible with contact dermatitis is described below in more detail. We 
propose that chrysotherapy can provoke an exacerbation of, or may induce, contact 
hypersensitivity to nickel. 
CASE REPORT 
A 71-year-old woman with seronegative 
rheumatoid arthritis had been on non­
steroidal anti-inflammatory drugs and 
hydroxychloroquine. After 5 months the 
hydroxychloroquine was replaced by in­
tramuscular aurothioglucose 50 mg 
weekly and 10 mg prednisone daily. She 
responded well; chrysotherapy was re­
duced to 50 mg every 3 weeks, and corti­
costeroids were tapered off. After she 
had been on gold therapy for 3 months 
she had an itching erythema of the neck 
and wrist. Seven months later she had a 
severe maculopapular confluent rash in 
both antecubilal fossae, on the wrists, 
and underneath the straps of her bras­
siere and her necklace. She recalled sim­
ilar reactions to jewellery many years be­
fore but she had been wearing jewellery 
without problems for several years. Bi­
opsy of an erythematous papule was 
compatible with allergic contact derma­
titis. Patch testing evinced a strong reac­
tion to nickel sulphate and cobalt chlo­
ride but not to gold chloride. The lesions 
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cleared within a few weeks of discontin­
uation of chrysotherapy and the patient 
was again able to wear jewellery without 
significant skin reaction. When gold was 
started again the severe maculopapular 
rashes recurred, disappearing once more 
when gold was discontinued. 
COMMENT 
Contact hypersensitivity to metallic gold 
is uncommon and is even rarer after sys­
temic gold treatment. It can be difficult 
to differentiate gold from nickel contact 
dermatitis. ' Patient В refused patch 
testing. In patients A an С a gold chloride 
patch test was negative but both reacted 
strongly to nickel. Two patients with con­
tact-dermatitis-like eruption had had 
dermatitis due to jewellery and we sug­
gest that they had been sensitized to 
nickel before chrysotherapy and that 
chrysotherapy was responsible for an ex­
acerbation of the contact hypersensitivi-
Table I. Characteristics of 10 patients with contact dermatitis or gold dermatitis 
Patient 
Contact 
dermatitis 
A(F,71) 
B(F,74) 
C(F,64) 
Gold 
dermatitis 
D(M,76) 
E(M,52) 
F(F,56) 
G(F,47) 
H(M,76) 
I(F,68) 
J(M,75) 
cumulative 
dose of 
gold (mg) 
1360 
910 
2000 
1210 
1610 
1410 
1010 
2010 
2010 
1210 
Site 
Face, neck 
Neck 
Wrist, under 
brassière 
Legs, arm, 
back 
scrotum 
Auditory 
canal 
Stomatitis 
Legs, hands, 
buttock 
Legs, arms 
Trunk, legs 
Legs 
Previous 
Sensitisation 
Yes 
No 
Yes 
No 
No 
No 
No 
No 
No 
No 
Pruritus 
+ 
+ 
+ 
-
+ 
+ 
+ 
+ 
+ 
+ 
Time to 
recover* 
3-4 wk 
4 wk 
NA 
3mo 
8 mo 
2 mo 
2 mo 
4 mo 
4 mo 
3mo 
: After discontinuation of chrysotherapy; NA = not applicable 
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Chiysotherapy provoking contact hypersensitivity 
ty-
Two possible explanations come to mind: 
the impairment of delayed type cutane­
ous hypersensitivity often seen in rheu­
matoid arthritis may have been reversed 
by chrysotherapy, or the gold injections 
were contaminated with nickel in the 
drug or in the needle. 
Neither in patient A, tested 8 months 
after the final withdrawal of chrysothe­
rapy, nor in patient C, tested 2 weeks 
after an intramuscular injection of auro-
thioglucose, was an anergic response 
found on assessing cutaneous hypersen­
sitivity to seven common recall antigens. 
We also measured nickel concentrations 
in aurothioglucose (Auromyose ), be­
fore and after passage through an in­
jection needle, by inductively coupled 
plasma atomic emission spectroscopy 
(Netherlands Energy Research Founda­
tion ECN; measurement error 10%). 
The amounts were 167 ng/g before and 
154 ng/g after passage, indicating that the 
nickel is more likely to come form the 
aurothioglucose than from the needle. 
No data are available on whether such 
small amounts of nickel can cause sensi­
tization to nickel or an exacerbation of 
contact allergy. However, delayed skin 
allergic reactions to nickel have been re­
ported after intradermal administration 
of a local anaesthetic contaminated with 
nickel ' and after intravenous infusions 
via metallic cannulac; and Boss et al. 
reported a sensitization rate of 20% from 
ear piercing. 
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ABSTRACT 
The long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) was studied 
in a consecutive sample of 148 patients with recently diagnosed rheumatoid arthritis. 
A survival analysis was done in which treatment terminations due to side effects and 
to insufficient therapeutic effect were used as index causes. Cumulative drug 'survival' 
of indomethacin with treatment terminations due to untoward reactions as end points 
was significantly less compared to naproxen and diclofenac (p < 0.001). No significant 
difference with termination due to lack of efficacy as index cause was observed 
(p > 0.90). No influence of sex or age on the drug 'survival' with the different endpoints 
mentioned above could be established. 
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are one of the most 
frequently prescribed drug categories. 
Especially in the treatment of Rheuma-
toid Arthritis (RA) they are often used 
for many years, usually in combination 
with second-line antirheumatic drugs. 
Huskisson et al. showed that there is a 
great interindividual variability concern-
ing both therapeutic and unwanted ef-
fects of these drugs. In clinical trials, 
comparable efficacy and toxicity have 
been shown for most NSAIDs. The studi-
es, however, on which these conclusions 
are based, mostly concern small numbers 
of selected patients, who were studied 
during a relatively short period of time 
and whose drug therapy mainly consisted 
of NSAIDs. Therefore, some differences 
between results of clinical trials and 'ex-
perience in community* may exist, justi-
fying doubt about conclusions for 'every-
day practice' based on such 'experi-
ments' under well-defined, and rather 
2 3 . 
ideal trial conditions. The aim of this 
study was to evaluate the number, the 
duration of treatment and the reasons for 
discontinuing therapy with NSAIDs ad-
ministered to RA patients in 'everyday 
practice,' in which combination therapy 
with second-line drugs is not unusual. 
PATIENTS AND METHODS 
Patients. Starting January 1985, all con-
secutive patients attending the Nijmegen 
University Hospital with 'definite' or 
'classical' rheumatoid arthritis diag-
nosed recently (within one year) accord-
ing to the 1958 American Rheumatism 
Association criteria, who had not pre-
viously received second-line antirheu-
matic drugs, were asked to participate in 
a long-term prospective study. By Au-
gust, 1989148 patients entered the study. 
Two patients who fulfilled the inclusion 
criteria were not included because of an 
unrelated life threatening disease. One 
patient refused to participate. The pa-
tients were treated by different rheuma-
tologjsts of the department. In addition, 
the patients were seen monthly by a re-
search nurse who collected quantitative 
clinical and laboratory data comprising 
duration of early morning stiffness, Rit-
chie articular index, grip strength using 
a sphygmomanometer (Martin Vigori-
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meter), pain score using a visual ana-
logue scale, ESR by Westergren's 
method and hemoglobin. Furthermore, 
the patients were asked open standard 
questions about their well-being and 
complaints. Prescription of NSAIDs was 
primarily based on the Hospital Drug 
Formulary allowing for 6 NSAIDs [Ibu-
profen, naproxen, piroxicam, diclofenac, 
indomethacin and an aspirin preparation 
(Ascal , ACF Roterfarma, the Nether-
lands)]. To optimize patient compliance 
and to avoid adverse drug reactions, all 
available formulations (slow release 
form; suppository) and administration of 
antacids and H2-blockers were permit-
ted. Furthermore, patients were allowed 
to vary the dose within the limits pre-
scribed by the treating physician. If 
judged necessary concomitant drug 
treatment with either disease modifying 
anti-rheumatic drugs (DMARDs) or 
prednisone was allowed. The use of 
NSAIDs was recorded as to starting 
date, maximal dose administered, stop-
ping date, reason for discontinuation and 
side effects starting with the drug the 
patient was taking at the time of referral. 
For this purpose specific data collection 
forms were used. When the same NSAID 
was prescribed to a patient twice this was 
regarded and registered as two separate 
treatment courses. In case of triplicate 
prescription, only the first and last 
courses were included in the analysis. 
Statistics. Standard methods of survival 
analysis (Kaplan-Meier, 1957) were 
used, in which treatment terminations 
due to side effects and/or lack of efficacy 
were taken as endpoints. For patients 
who stopped treatment because of 're-
mission of the disease' (n = 22) or 'other 
reasons' (n = 3) viz. desired pregnancy, 
death from an unrelated cause or fear of 
drugs, and for patients who did not reach 
one of these endpoints the observation 
time was censored. The Lee-Desu test 
was used to compare the administration 
times of the different NSAIDs. 
RESULTS 
During the observation period NSAIDs 
were prescribed 217 times in 143 pa-
tients. More than 90% of the patients 
were concomitant ly t r ea ted with 
DMARDs. Prednisone was only pre-
scribed sporadically. In table I the num-
ber of different NSAIDs administered 
Table I. Number of NSAIDs used in the period of follow-up and mean ranking order of prescription 
drug number of 
prescriptions 
101 
47 
46 
14 
5 
4 
mean ranking 
order' 
1.9 
2.2 
2.2 
3.0 
2.0 
2.8 
naproxen 
indomethacin 
diclofenac 
piroxicam 
Ibuprofen 
ketoprofen 
Total 217 
* Not significantly different 
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Table II. Clinical characteristics at the start of NSAID treatment 
number of prescriptions 
mean age 
(years ±SD) 
percentage over 
55 years of age 
sexF/M 
index of disease activity 
(Mallya ±SD) 
mean maximal dose 
(mg ±SD) 
indomethacin 
47 
54.1 (±12.3) 
4 9 % 
30/17 
2.60 (±034) 
132 (±51) 
naproxen 
100 
55.7 (±14.1) 
4 8 % 
62/38 
255 (±0.60) 
978 (±250) 
diclofenac 
44 
52.6 (±15.2) 
5 0 % 
29/15 
2.68 (±0.61) 
161 (±40) 
during the follow-up period is shown. 
Three NSAIDs - indomethacin (cap­
sules: 25 mg, 50 mg, slow release form 75 
mg; suppository: 50 mg, 100 mg), na­
proxen (tablets: 250 mg, 500 mg; suppos­
itory: 250 mg, 500 mg) and diclofenac 
(tablets: enteric coated 25 mg, 50 mg, 
slow release form 100 mg; suppository: 
50 mg, 100 mg) - accounted for almost 
90% of the total number of prescriptions. 
Because of the small number of the other 
drugs, statistical analysis could be done 
only for these three NSAIDs. Correction 
for triplicate prescription in two patients 
and an obscure reason for treatment ter­
mination in one prescription, resulted in 
191 courses in 135 different patients to be 
analyzed. No statistically significant dif­
ference in the rank order of the adminis­
tration of the three drugs was found 
(p >0.20, Kruskall-Wallis test)(Table I). 
No statistically significant difference in 
the distribution of the three NSAIDs 
over sex and age was observed (p > 0.90, 
χ -tests). Nor did the disease activity as 
expressed by the index of disease activity 
according to Mallya et al.7 at the start of 
the NSAID therapy differ significantly 
(p >0.50, analysis of variance) (Table II). 
Survival analysis 
Figure 1 presents the cumulative drug 
'survival' for indomethacin, naproxen 
and diclofenac with treatment termina­
tion due to the occurrence of side effects 
as endpoints. By six months 35% of the 
patients taking indomethacin, 8% of 
those taking naproxen and 15% of those 
taking diclofenac had stopped treatment 
due to adverse drug reactions. At one 
year the proportions were: indomethacin 
41%, naproxen 14% and diclofenac 19%. 
Thereafter, a flattening of the curves is 
observed. The difference between indo­
methacin and the other two NSAIDs was 
statistically significant (p< 0.001, Lee-
Dcsu test). 
In figure 2 cumulative drug 'survival' with 
insufficient therapeutic effect as the in­
dex cause is shown. There are no appar­
ent differences between the three treat­
ment groups (p>0.90, Lce-Desu test). 
In order to compare the results of the 
present survival study with the literature 
we also studied the drug 'survival' with 
treatment termination due to the combi­
nation of the two index causes mentioned 
above. The incidence of treatment termi­
nation due to combined lack of efficacy 
and toxicity was significantly greater in 
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Figure 1. Cumulative drug 'survival' of indomethacin (—), naproxen (—) and diclofenac ( · · · ) with 
treatment termination due to toxicity as endpoint 
·/· on therapy 
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Figure 2. Cumulative drug 'survival' of indomethacin (—), naproxen (—) and diclofenac ( · · · ) with 
treatment termination due to insufncient therapeutic effect as index cause 
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Table III. Discontinuation of NSAID treatment during follow-up 
drug 
indomethacin 
naproxen 
diclofenac 
Total 
number 
47 
100 
44 
191 
lack of 
efficacy 
4 
13 
5 
22 
side 
effects 
19 
15 
6 
40 
combination 
1 
1 
1 
3 
remission 
5 
12 
5 
22 
censored 
18 
59 
27 
104 
the indomethacin-treated patients 
(p<0.01, Lee-Desu test). By six months 
42% of the patients taking indomethacin, 
16% of those taking naproxen and 24% 
of those taking diclofenac had stopped 
treatment. At twelve months the propor-
tions were 47% for indomethacin, 23% 
for naproxen and 26% for diclofenac. 
Reasons for discontinuing NSAID 
treatment and side effect profiles 
Of the 191 times indomethacin, naproxen 
and diclofenac were prescribed, discon-
tinuation of treatment occurred 40 times 
because of side effects, 22 times because 
of lack of efficacy, 3 times because of 
both reasons and 22 times because of 
remission of the disease (Table III). In 
104 prescriptions neither lack of efficacy 
nor side effects yet has been proved. 
The adverse reactions most frequently 
encountered were gastrointestinal com-
plaints. The side effect profiles of the 
three NSAIDs studied are shown in 
Table IV. Due to small numbers further 
statistical evaluation of these figures was 
not feasible. 
Influence of sex and age on the 
'survival' of indomethacin, naproxen 
and diclofenac 
For each of these drugs life-table analysis 
comparing both sexes was done. No sig-
nificant difference was found in survival 
with toxicity, lack of efficacy, or their 
combination as endpoints. The same was 
done comparing two different age 
groups (over vs under 55). No influence 
of age on the survival with the different 
endpoints mentioned above could be es-
tablished. 
DISCUSSION 
Because of the large number of NSAIDs 
available in the Netherlands, the compa-
rable efficacy and toxicity for the various 
NSAIDs as shown in controlled short-
term studies, and the great interindivi-
dual variability concerning both toxic 
and beneficial effects, our hospital insti-
tuted a Hospital Drug Formulary allow-
ing for 6 NSAIDs. Although it has been 
indicated by Huskisson that it is possible 
to treat rheumatic complaints satisfacto-
rily with 4 different NSAIDs for a short 
period of time, no data are available on 
the long term. In our study it is shown that 
of the 217 prescriptions, 194 were for 
indomethacin, naproxen and diclofenac, 
indicating that just three NSAIDs in most 
cases appear sufficient for NSAID treat-
ment in RA patients for several years as 
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Table Г . Side effect profiles of indomethacin, naproxen and diclofenac 
indomethacin 
η = 47 
naproxen 
η = 100 
diclofenac 
η = 44 
cutaneous 
gastrointestinal 
central nervous 
miscellaneous 
Total' 
1 
14 
7, 
23 
4 
11 
18 
. In five patients two different adverse reactions occurred simultaneously 
Lbleeding of the bladder in a patient with cancer of the prostate 
$ irritation of nose and throat 
edema of lower extremities 
judged by the patient and the attending 
physician. 
For the evaluation of drug toxicity and 
certainly for evaluating efficacy, the use 
of survival analysis with drug discontinu­
ation as index cause is less sensitive than 
a controlled clinical trial. Furthermore, 
without the benefit of proper randomiza­
tion a 'clear-cut' statistical comparison of 
the various NSAIDs with regard to their 
toxicity and efficacy docs not appear fea­
sible. However, on account of the long-
term follow-up, the large number of pa­
tients, the close reflection of clinical 
practice and the fact that no differences 
between the treatment groups in con­
founding factors such as the rankorder of 
prescription and the initial disease activ­
ity were found, some conclusions may be 
drawn from this study. Comparing indo­
methacin, naproxen and diclofenac it is 
shown that treatment termination due to 
side effects occurred more frequently in 
the indomethacin-treated patients. The 
side effect profiles and the percentages 
of discontinuation due to lack of efficacy 
were similar in the three treatment 
groups. In contrast to the findings of 
Capell et al. our survival analysis with 
treatment terminations due to lack of 
efficacy or adverse drug reactions as end-
points showed a smaller 'survival' of in­
domethacin compared to naproxen. It is 
of interest that the proportions of pa­
tients completing one year of indome­
thacin therapy are comparable in both 
studies (61% vs 53%), but that the per­
centage completing one year of naproxen 
treatment is about twice as large in our 
study (36% vs 77%). As a linear dose-re­
sponse relationship has been demon­
strated by Day et al, an explanation for 
this discrepancy might be the difference 
in dose administered: in the study of 
Capell et al. doses up to 750 mg/day were 
administered, while in our study a mean 
maximal dose of about 1000 mg was used. 
With respect to duration of administra­
tion of naproxen and indomethacin, our 
results are consistent with the extended 
observations recently published by 
Luggen et al. 
In accordance with the literature no 
differences in 'efficacy time' were found 
between indomethacin, naproxen and di­
clofenac. 
Based on the findings of Upton et al. 
that elderly compared to the young have 
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only half the ability to eliminate unbound 
naproxen, Brater et al. advocated halv­
ing the dose in treating patients of ad­
vanced age. However, we found no 
difference in the administration time of 
naproxen (and indomethacin, diclofe­
nac) between patients over and under 55 
years of age, in spite of the same (maxi­
mal) dose used in both age groups. Van 
den Ouweland et al. showed that RA 
patients with active compared to inactive 
disease may have altered naproxen phar-
macokinetics, which might lead to 
changes in toxicity and/or efficacy of the 
drug. At the start of the NSAID therapy 
and at the moment untoward drug reac­
tions occurred (data not shown) no dif­
ferences in disease activity between the 
treatment groups were found, indicating 
that this phenomenon is unhkely to have 
influenced our study results. 
In conclusion our prospective study of 
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ABSTRACT 
The administration time of second-line antirheumatic drugs was prospectively studied 
in a consecutive sample of 245 patients with recently diagnosed rheumatoid arthritis. 
Cumulative drug 'survival' of aurothioglucose with treatment termination due to 
toxicity was significantly less compared with hydroxychloroquine. With regard to lack 
of efficacy as index cause, the administration time of hydroxychloroquine was signif-
icantly less than that of either aurothioglucose or sulfasalazine. Treatment termina-
tion due to lack of efficacy or combined insufficient therapeutic response and toxicity 
proved to be influenced by the initial disease activity and by the rank order of 
prescription. 
Disease Modifying Anti-Rheumatic Drugs (DMARDs) play a key role in 
the treatment of Rheumatoid Arthritis 
(RA). Their use is limited, however, by 
the fact that a substantial percentage of 
patients have to be taken off treatment 
because of lack of efficacy or serious side 
effects. Clinical trials provide informa-
tion on efficacy and toxicity only on short 
or medium term basis. Since RA is a 
progressive and longstanding disease, 
necessitating drug treatment for many 
years, it is important to collect long-term 
data, as well. In several long-term studies 
the drop-out rates for various second-
line antirheumatic drugs due to toxicity 
or inefficacy are compared using 'life-
table analysis.' However, these studies 
are of a retrospective study design ' • · ^ 
or concern RA patients with relatively 
long duration of disease. ' ' ' ' In a pro-
spective design we studied the use of 
second-line antirheumatic drugs in re-
cently diagnosed RA. Survival analysis 
was used to compare the administration 
times of parenteral gold, hydroxychloro-
quine, sulfasalazine and d-penicillamine. 
PATIENTS AND METHODS 
Patients. Starting January 1985 all con-
secutive patients attending the Nijmegen 
or the Groningen University Hospital 
with recent onset ( < 1 year) rheumatoid 
arthritis were selected to participate in 
the study. Patients fulfilling the 1958 
American Rheumatism Association cri-
teria who had not previously received 
second-line antirheumatic drugs, were 
asked for their informed consent. Up to 
the end of 1989 272 patients enlered the 
study. During the study period six pa-
tients, fulfilling the inclusion criteria 
were not included: three patients be-
cause of an unrelated life-threatening 
disease and three patients refused to par-
ticipate. The patients were treated by 
rhcumatologists of both Rheumatology 
departments according to the same pro-
tocol: Drug treatment was started with a 
Non Steroidal Anti-Inflammatory Drug 
(NSAID). After a period of at least four 
weeks a second-line drug could be 
added. It was recommended to begin 
with hydroxychloroquine (200 mg b.i.d. 
during 24 weeks, thereafter 200 mg 
daily), sulfasalazine (Enteric Coated, ini-
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tial daily dose of 500 mg, increased by 500 
mg every week to a maximal dose of 2000 
mg per day) or oral gold (6 mg daily). 
Thereafter aurothioglucose (started with 
a test dose of 10 mg, followed by 50 mg 
weekly during 20 weeks, thereafter 50 mg 
every 2 - 4 weeks) or d-penicillamine (250 
- 750 mg daily) could be administered. 
However, if judged necessary it was al-
lowed to start second-line treatment with 
one of the latter drugs or to reduce or 
increase the recommended dose. Treat-
ment was never commenced with metho-
trexate (7.5 mg weekly) or azathioprine 
(100 - 150 mg daily), drugs regarded as 
'third-line' treatment at that time. Com-
bined DMARD treatment was not al-
lowed. If necessary corticosteroids could 
be administered as adjuvant therapy. 
The patients were seen monthly by spe-
cially trained research nurses who col-
lected quantitative clinical and labora-
tory data such as number of swollen 
joints, Ritchie articular index, general 
health using a visual analogue scale of 10 
cm (0 = best possible, 10 = worst possi-
ble), ESR by Westergren's method and 
IgM rheumatoid factor (ELISA, normal 
< 5 IU/1). Based on the Ritchie score, 
number of swollen joints, ESR and gen-
eral health a 'disease activity score' 
(DAS) was calculated according to van 
der Heijde et al. ' Furthermore, at 
each monthly visit the patients were 
asked open standard questions about 
their well-being and complaints. The use 
of DMARDs was recorded as to starting 
date, dose, stopping date, reason for dis-
continuation and side effects. For this 
purpose specific data collection forms 
were used. Since operational criteria for 
adverse drug reactions are needed and 
suitable laboratory and clinical tests to 
confirm causality are generally not avail-
able, the causal relationship between the 
clinical manifestation and the suspected 
drug was estimated retrospectively using 
the algorithm described by Naranjo et 
al. By determining this 'Naranjo-score' 
(range: -4 to 13) which is composed of the 
sum of the scores of 10 different items 
based on the course, the time relation-
ship and the exclusion of alternative 
causes, adverse drug reactions can be 
assigned to the following probability cat-
egories: 'doubtful:' score <0; 'possible:' 
1 to 4; 'probable:' 5 to 8; and 'definite:· 
>9. This adverse drug reaction probabil-
ity scale showed a consensual, content 
and concurrent validity tested on ran-
domly selected alleged adverse drug re-
actions described in the literature. 
Table I. Number and proportion (%) of prescriptions of hydroxychloroquine, sulfasalazine, aurothio-
glucose and d-penicillanune as the first to fourth DMARD 
total rank order 
(mean ± SD) 
hydroxychloroquine 
sulfasalazine 
aurothioglucose 
d-penicillamine 
2(2) 
11(9) 
13 (14 
8 24) 
135 1.10 ± 0.35 
118 1.39 ± 0.65 
96 1 88 ± 0.67 
34 2.15 ± 0.83 
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Temporary treatment interruptions due 
to any reason for a period of less than one 
month for sulfasalazine or methotrexate 
and less than two months for hydroxy-
chloroquine, oral gold, aurothioglucose, 
d-penicillamine and azathioprine were 
ignored. When the same drug was pre-
scribed to a patient for more than one 
separate period only the first treatment 
course was included in the analysis. 
Statistics. Standard methods of survival 
analysis (Kaplan-Meier, 1957) were 
used, in which treatment terminations 
due to side effects and/or lack of efficacy 
were taken as end points. For patients 
who stopped treatment because of 're-
mission of the disease,' death or 'other 
reasons' and for patients who did not 
reach one of these end points the ob-
servation time was censored due to clos-
ing data collection at the end of 1989. The 
Cox's proportional hazards (PH) model 
was used to compare the administration 
times of the DMARDs. In general the 
PH model fitted very well to the data. 
RESULTS 
During an observation period of almost 
5 years a DMARD was prescribed 432 
times in 245 patients. In 27 patients no 
second-line drugs were prescribed. The 
numbers of times the various DMARDs 
were administered were: hydroxychloro-
quine 135, sulfasalazine 118, aurothio-
glucose 96, d-penicillamine 34, metho-
trexate 18, azathioprine 18 and oral gold 
13. Because of the small number of pre-
scriptions of oral gold, methotrexate and 
azathioprine, survival analysis could be 
done only for hydroxychloroquine, sul-
fasalazine, aurothioglucose and d-peni-
cillamine. With respect to these last four 
DMARDs 140 patients were treated with 
1 DMARD, 72 with 2,30 with 3 and 3 with 
4 consecutive drugs during the observa-
tion period. The numbers and propor-
tions of prescriptions of hydroxychloro-
quine, sulfasalazine, parenteral gold and 
d-penicillamine as the first to fourth 
DMARD and the mean rank orders of 
prescription are presented in table I. As 
expected, the mean rank orders differed 
significantly (p < 0.0001, analysis of vari-
ance). 
No statistical difference in the distribu-
tion of these drugs over sex and age was 
found. As expected, the disease activity 
at the start of the DMARD treatment 
was higher in the gold and d-peni-
cillamine treated patients compared to 
those treated with hydroxychloroquine 
or sulfasalazine (DAS; range: 0.87 to 
7.10; mean (±SD): 4.46 (±1.04); hy-
droxychloroquine: 4.28 (±1.12); sulfa-
salazine: 4.25 (±0.98); gold i.m.: 4.93 
(±0.85); and d-penicillamine: 4.63 
(±0.83)). 
Survival analysis 
Figure 1 presents the estimated cumula-
tive drug 'survival' of hydroxychloro-
quine, sulfasalazine, aurothioglucose 
and d-penicillamine with treatment ter-
mination due to untoward drug reactions 
as index cause. By one year the estimated 
proportion of patients who have to stop 
second-line treatment because of side ef-
fects is 12% of the patients taking 
hydroxychloroquine, 18% of those taking 
sulfasalazine, 29% of those treated with 
parenteral gold and 13% of those taking 
d-penicillamine. At year two the propor-
tion who will discontinue aurothioglu-
cose therapy is 39%. No further treat-
ment terminations due to toxicity arc 
likely to occur among the hydroxychloro-
quine, sulfasalazine and d-penicillamine 
treated patients. Overall statistic com-
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number о 
presenp-
tions 
hydroxychloroquine 135 
sulfasalazine 118 
aurothioglucose 96 
d-penicillamine 34 
Total 383 
# both lack of efficacy and toxu 
' . end point not reached due lo 
lack of side effects combina-
efficacy tion 
(%) (%) (%) 
69 (51) 13 (10) 1 (1) 
22 (19) 13 (11) 5 (4) 
23 (24) 25 (26) 5 (5) 
7(21) 4(12) 0(0) 
121 (32) 55 (14) 11 (3) 
occurring simultaneously in the 
sing data collection 
remission others end point 
not 
reached 
(%) (%) (%) 
5 (4) 7 (5) 40 (30) 
4 (3) 4 (3) 70 (59) 
5 (5) 2 (2) 36 (38) 
1 (3) 1 (3) 21 (62) 
15 (4) 14 (4) 167 (44) 
patient 
Table II End points reached during follow-up 
parison reveals no clear significant dif­
ference between the four treatment 
groups. After censoring for side effects 
with only a 'possible' or 'doubtful' causal 
relationship (i.e. 'Naranjo score' less 
than 5) the statistical difference becomes 
highly significant (p< 0.001, PH model). 
When comparing the four drugs by pairs 
a significant difference in administration 
time, after censoring for 'Naranjo-score' 
less than 5, is found only between au­
rothioglucose and hydroxychloroquine 
(p< 0.0001, PH model with Bonferroni 
correction for multiple testing). 
In figure 2 the estimated cumulative drug 
'survival' with treatment termination due 
to lack of efficacy as end point is shown. 
By one year 44% of the patients taking 
hydroxychloroquine, 22% of those taking 
sulfasalazine, 20% of the patients treated 
with aurothioglucose and 24% of those 
taking d-penicillamine are estimated to 
stop. At two years the proportions are 
hydroxychloroquine 61%, sulfasalazine 
46%, aurothioglucose 43% and d-peni­
cillamine 43%. Tested simultaneously 
the four DMARDs differ significantly 
(p< 0.003, PH model). When tested by 
pairs a significant difference is found be­
tween aurothioglucose and hydroxy­
chloroquine and between sulfasalazine 
and hydroxychloroquine (p<0.01, re­
spectively ρ < 0.02, PH model with Bon­
ferroni correction). 
With regard to insufficient therapeutic 
response and/or toxicity as index cause a 
statistically significant difference be­
tween the four drugs is found (p<0.05, 
PH model). After censoring for 'Nar-
anjo-scores' less than 5, this difference 
increases (p<0.03, PH model)(fig 3). 
However, when tested by pairs no signif­
icant differences between the treatment 
groups are observed. 
Influence of disease activity and rank 
order of prescription on drug survival 
Since significant differences in initial dis­
ease activity and rank order of prescrip­
tion between the four treatment groups 
were found, the influence of these factors 
was studied using the PH model with the 
drugs as covariates. No statistically sig­
nificant influence of disease activity or 
rank order on the termination rate due to 
untoward drug reactions was observed, 
whether or not censoring for 'Naranjo-
scores' less than 5 was done. With regard 
to treatment termination due to lack of 
efficacy or due to either insufficient ther-
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apeutic response or toxicity the survival 
period was decreased by a high initial 
disease activity (DAS). With respect to 
these end points, drugs with high rank 
orders of prescription were discontinued 
earlier than drugs with low rank orders, 
as well. The magnitude and direction of 
these effects can be expressed in so-
called 'conditional relative risks' (CRR). 
A CRR reflects the relative risk of the 
occurrence of an event (e.g. treatment 
discontinuation due to lack of efficacy) 
during a certain short period of time (e.g. 
one month) given the condition of an 
equal eventfree period of treatment. The 
CRRs and the corresponding 95% con-
fidential intervals for the end points men-
tioned arc tabulated in table V. For ex-
ample, with respect to disease activity 
and treatment termination due to lack of 
efficacy the CRR is 1.45. This means that 
comparing 'eventfree patients,' the 
short-term risk of discontinuing therapy 
due to insufficient response for a patient 
with an initial DAS of 4 is 1.45 times 
larger than that for a patient with an 
initial score of 3. This CRR holds within 
each type of DMARD. 
Corrections for disease activity and rank 
order of prescription were made in the 
comparison of the separate drugs by 
using the PH model. 
DISCUSSION 
When comparing the median adminis-
tration time with combined toxicity and 
lack of efficacy as end point in the pres-
ent survival analysis with results from the 
literature similar figures are found for 
the median periods of prescription of 
hydroxychloroquine, parenteral gold 
and d-penicillamine. However, in one 
study^ a median 'survival' of gold beyond 
60 months has been reported. But, since 
the patients who entered this study had 
already received an initial gold treatment 
Table III. Number of adverse reactions, 'Naranjo-scores' and side effect profiles of hydroxychloro-
quine, sulfasalazine, parenteral gold and d-pcnicillamine 
number 
'Naranjo score' 
mean (±SD) 
cutaneous 
gastrointestinal 
thrombocytopenia 
leukopenia 
proteinuria 
central nervous system (headache, dizziness etc) 
others 
Total 
hydroxy-
chloroquine 
135 
4.57 (±1.28) 
9 
5 
0 
0 
0 
0 
0 
14 
sulfasalazine 
118 
5.89 (±1 
6 
12 
0 
1 
0 
6 
1* 
26 
.67) 
gold i.m. 
96 
5.94 (±1.74) 
21 
3 
2 
2 
6 
2 
S 
40 
d-peni-
cillamine 
34 
4 JO (±1.00) 
1 
1 
1 
0 
1 
1 
0 
5 
total 
383 
37 
21 
3 
3 
7 
9 
5 
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*: periorbital edema 
: corneal ulcers; vulvitis; loss of hair; increase of transaminases and alkaline phosphatase 
In 12 patients 2, and in 4 patients 3 different side effects were observed 
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Figure 1. Probability of treatment termination due to toxicity. Estimated proportion (±SE) of 
patients on hydroxychloroquine (—), sulfasalazine (—), aurothioglucosc ( · · · ) and 
d-penicillamine (- - - ·) treatment over time 
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Figure 2. Probability of treatment termination due to lack of efficacy. Estimated proportion (±SE) 
of patients on hydroxychloroquine (—), sulfasalazine (—), aurothioglucosc ( · · · ) and 
d-penicillamine ( - · - ' ) treatment overtime 
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of at least a cumulative dose of 1 g, a frank 
selection bias must be assumed in this 
report. It is of interest that the median 
administration time with treatment ter-
mination due to combined toxicity and 
lack of efficacy of sulfasalazine in our 
hands is about twice that revealed in two 
other studies. ' For lack of data in the 
literature no comparisons of the discon-
tinuation rates of the various DMARDs 
due to side effects or insufficient thera-
peutic response alone could be made. 
Comparing the administration times of 
the four DMARDs studied in the present 
survival analysis a higher discontinuation 
rate due to insufficient response is found 
for hydroxychloroquine compared to au-
rothioglucose and sulfasalazine. With re-
gard to toxicity as index cause a greater 
discontinuation rate of aurothioglucose 
compared to hydroxychloroquine is ob-
served. It is shown that the latter became 
more pronounced, when restricted to 
side effects with a 'clear' causal relation-
ship (i.e. a 'Naranjo score' of 5 or more). 
At three years the risk of treatment ter-
mination due to combined lack of effi-
cacy and toxicity was similar for the four 
drugs studied (hydroxychloroquine: 
7 3 % ( ± 5 % ) ; sulfasalazine: 6 1 % 
(±11%); aurothioglucose: 72% (±7%) 
and d-penicillamine: 52% (±13%)). 
A problem in comparing and interpre-
ting results of survival studies are differ-
ences in rank order of the prescribed 
drugs, as one may expect that patients 
treated with a second, third or even a 
fourth DMARD are more likely to de-
velop side effects or are less likely to 
improve on the ensuing drug due to se-
lection to more resistant cases. A statis-
tically significant influence of the rank 
order of prescription on the 'survival' 
with toxicity as index cause was not 
found. However, we found a statistically 
significant influence of the rank order on 
the administration time with treatment 
termination due to lack of efficacy or due 
to the combination of insufficient thera-
peutic response and toxicity: the higher 
the rank order of prescription, the lower 
the drug 'survival.' Since spontaneous re-
missions are more likely to occur in the 
beginning of the disease and all patients 
included in this study had early rheuma-
toid arthritis, our results might have been 
influenced by study design. In addition, 
the guidelines given to the treating rheu-
matologists have had some effect on the 
issue of rank order. Although, the rank 
order was not totally fixed (table 1). 
Another difficulty in comparing the 'sur-
vival' of DMARDs are differences in ini-
tial disease activity. It is hard to presage 
Table IV. Conditional relative risks (CRR) and 95% confidential intervals 
index cause: lack of efficacy lack of efficacy and/or toxicity 
(all) (Naranjo-corrected) 
rank order 1.49(1.01-2.20) 
1.19-1.75) disease activity score 1.45 (1.1 
1.37 (1.01 -1.87) 
1.30 (1.05 -1.46) 
1.40 (1.01 -1.93) 
1.31 (1.10 -1.55) 
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Figure 3. Probability of treatment termination due to efficacy and/or toxicity. Estimated proportion 
(±SE) of patients on hydroxychloroquine (—), sulfasalazine (—), aurothioglucose ( · · ·) and d-peni-
cillamine ( - · - · ) treatment over time 
what influence disease activity may have 
on the results. With respect to toxicity it 
may be expected that a high disease ac-
tivity might be associated with an in-
crease in discontinuation due to side ef-
fects (e.g. by hypoalbuminemia). No sta-
tistically significant influence of the dis-
ease activity as expressed by DAS on the 
termination due to untoward drug reac-
tions was found. More active disease 
might be more resistant to therapy, but 
may also have a greater capacity for 
amelioration. We found that active dis-
ease predisposes to a more pronounced 
drop-out due to insufficient therapeutic 
response and due to the combination 
with toxicity. The latter is probably 
driven by the influence of the DAS on the 
drug 'survival' with lack efficacy as end 
point. Nevertheless, the two treatment 
groups with the highest initial disease 
activity (aurothioglucose and d-peni-
cillamine) appeared to have the longest 
drug 'survival' with regard to efficacy. 
For hydroxychloroquine the pronounced 
tendency to treatment termination can-
not be explained by a high initial disease 
activity. 
Accordingly, rank order of prescription 
and disease activity influenced the drug 
'survival' with lack of efficacy as index 
cause. No influence of these was ob-
served on the drop-out rate due to toxic-
ity. 
Of course, without the benefit of proper 
randomization a 'clear-cut' statistical 
comparison of the administration times 
of the various DMARDs does not appear 
feasible. However, after analysis of the 
influence of confounders such as differ-
80 
DMARD survival in RA 
enees in initial disease activity and rank lack of efficacy goes on for about 2 years 
order of prescription, the following con- with all 4 DMARDs. 
elusions seem justified: the discontinua- For the evaluation of drug toxicity and 
tion rate due to side effects was more certainly for evaluating efficacy, the use 
pronounced in gold treated patients and of survival analysis with drug discontinu-
that due to lack of efficacy was greater in ation as end point is less sensitive than a 
the hydroxychloroquine group. Further- controlled clinical trial. However, due to 
more, it is shown that discontinuation the long-term follow-up, the close reflcc-
due to adverse drug reactions during hy- tion of everyday clinical practice and the 
droxychloroquine, sulfasalazine and d- large number of patients studied, the 
penicillamine therapy is restricted to the conclusions based on survival analysis 
first year of treatment, while discontinu- are of importance and may contribute to 
ation of chrysotherapy due to toxicity is the discussion on the controversies in 
extended over a much longer period. It is DMARD treatment. 
also shown that discontinuation due to 
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ABSTRACT 
Clinical and laboratory factors influencing the continuation of second-line antirheu-
matic drugs were prospectively studied using survival analysis in a consecutive series 
of 245 patients with recently diagnosed rheumatoid arthritis. A statistically significant 
influence of age, sex, serum IgA and HLA-DR3 on the discontinuation rate of 
chrysotherapy because of toxicity was observed. The continuation of sulfasalazine was 
diminished by advanced age and high rank order of prescription. With respect to 
efficacy, high initial disease activity appeared to predispose to treatment termination 
of hydroxychloroquine, sulfasalazine and d-penicillamine. Furthermore an influence 
of the rank order of prescription on discontinuation of sulfasalazine therapy because 
of lack of efficacy was found. Of interest is that discontinuation of hydroxychloroquine 
therapy because of lack of efficacy occurred less frequently in HLA-DR3 positive 
than in HLA-DR3 negative patients. Although these prognostic factors are of sec-
ondary importance in clinical practice, they may be of significance in the interpreta-
tion and comparison of clinical trials. 
Disease Modifying Anti-Rheumatic Drugs (DMARDs), also called 'sec-
ond-line anti-rheumatic drugs,' play a 
key role in the treatment of rheumatoid 
arthritis (RA). An important drawback 
in applying these drugs is the high inci-
dence of treatment discontinuation ei-
ther because of occurrence of side ef-
fects, or because of lack of sufficient 
therapeutic response. Several studies 
have shown that up to 70% of patients 
have to stop DMARD treatment within 
2 years. ' ' ' ^' Knowledge of factors 
predicting response to DMARDs on the 
one hand and of toxicity on the other 
could provide a better risk-benefit ratio. 
Until now only a few factors with a prog-
nostic value for efficacy have been de-
scribed. For instance the presence of 
HLA-DR3 antigen has been related to 
excellent respondership to parenteral 
gold treatment. With respect to side ef-
fects many reports on risk factors have 
been published. However, only on a few 
risk factors there is some agreement in 
the literature, and in these cases the 
prognostic value for occurrence of ad-
verse drug reactions (ADR) in a given 
patient is rather low. Therefore, their 
clinical usefulness is limited. In this study 
we investigated whether factors predict-
ing toxicity and/or efficacy could be 
determined from a longitudinal prospec-
tive follow-up study of patients with re-
cently diagnosed RA. Multiple clinical 
and laboratory variables present at the 
start of second-line treatment, the course 
of these variables over time, as well as at 
the time side effects occurred, were stud-
ied in relation to treatment termination. 
PATIENTS AND METHODS 
Patients 
Starting January 1985 all consecutive pa-
tients attending the Nijmegen or the 
Groningen University Hospital with re-
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Table I. Naranjo's adverse drug reaction probability scale 
1. 
2. 
6. 
7. 
10. 
Are there previous conclusive reports on this reaction? 
Did the adverse event appear after the suspected drug 
was administered9 
Did the adverse reaction improve when the drug was 
discontinued or a specific antagonist was administered? 
Did the adverse reaction reappear when the drug was 
readmimstered? 
Are there alternative causes (other than the drug) that 
could on their own have caused the reaction? 
Did the reaction reappear when a placebo was given'' 
Was the drug detected in the blood (or other fluids) in 
concentratrations known to be toxic9 
Was the reaction more severe when the dose was in-
creased, or less severe when the dose was decreased? 
Did the patient have a similar reaction to the same or 
similar drugs in any previous exposure? 
Was the adverse event confirmed by any objective evi-
dence? 
yes 
+ 1 
+2 
+ 1 
+ 2 
- 1 
- 1 
+ 1 
+ 1 
+ 1 
+ 1 
no 
0 
- 1 
0 
- 1 
+ 2 
+ 1 
0 
0 
0 
0 
do not score. 
know 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
total score: 
: from Naranjo et al 
cent onset ( < 1 year) rheumatoid arthri-
tis were selected to participate in the 
study. Patients fulfilling the 1958 Ameri-
can Rheumatism Association criteria 
who had not previously received second-
line antirheumatic drugs, were asked for 
their informed consent. Up to the end of 
1989 272 patients entered the study. 
Three patients were excluded because of 
an unrelated life-threatening disease and 
three patients refused to participate. The 
patients were treated by rheumatologists 
of both rheumatology departments ac-
cording to the same protocol: drug treat-
ment was started with a Non-Steroidal 
Anti-Inflammatory Drug (NSAID). 
After a period of at least four weeks a 
second-line drug might be added. It was 
recommended to start with hydroxychlo-
roquine (200 mg b.i.d. for 24 weeks, 
thereafter 200 mg daily), sulfasalazine 
(enteric coated, initial daily dose 500 mg, 
increased by 500 mg every week to a 
maximal daily dose of 2000 mg) or oral 
gold (6 mg daily). Thereafter aurothiog-
lucose (started with a test dose of 10 mg, 
followed by 50 mg weekly for 20 weeks, 
thereafter 50 mg every 2 - 4 weeks) or 
d-penicillamine (250 - 750 mg daily) 
could be administered. However, if 
judged necessary it was allowed to start 
second-line treatment with one of the 
latter drugs or to reduce or increase the 
recommended dose. Treatment was 
never commenced with methotrexate 
(7.5 mg weekly) or azathioprine (100 -
150 mg daily), drugs regarded as 'third-
line' treatment at the time. Combined 
DMARD treatment was not allowed. If 
necessary corticosteroids might be ad-
ministered as adjuvant therapy. The pa-
tients were seen monthly by specially 
trained research nurses who collected 
quantitative clinical and laboratory data 
such as weight, number of swollen joints, 
Ritchie articular index, general health 
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using a visual analogue scale of 10 cm (0 
= best possible, 10 = worst possible), 
ESR by Westergren's method, immuno­
globulins A (nephelometric: IgA, normal 
1.4 - 2.6 g/1), M (nephelometric: IgM, 
normal 0.7 -1.5 g/1) and G (nephelomet­
ric: IgG, normal 10.4 - 14.6 g/1), IgM 
rheumatoid factor (ELISA, normal < 5 
Ш/1), and antinuclear antibodies (ANA, 
indirect immunofluorescence on Hep-2 
cells). HLA-DR typing was done in each 
patient at entry using standard serologi­
cal procedures. Based on the Ritchie 
score, number of swollen joints, ESR and 
general health a 'disease activity score' 
(DAS) was calculated according to van 
der Heijde et al. ' Furthermore, at 
each monthly visit the patients were 
asked open standard questions about 
their well-being and complaints. The use 
of DMARDs was recorded as to starting 
date, dose, stopping date, reason for dis­
continuation and side effects. For this 
purpose specific data collection forms 
were used. Since operational criteria for 
ADR are needed and suitable laboratory 
and clinical tests to confirm causality are 
generally not available, the causal rela­
tionship between the clinical manifesta­
tion and the suspected drug was esti­
mated using the algorithm described by 
Naranjo et al. By determining this 'Nar­
anjo score' (range: -4 to 13) which is 
composed of the sum of the scores of 10 
different items based on the course, the 
time relationship and the exclusion of 
alternative causes, ADR can be assigned 
to the following probability categories: 
'doubtful:' score <0; 'possible:' 1 to 4; 
'probable:' 5 to 8; and 'definite:' > 9 
(Table I). 
Temporary treatment interruptions for 
any reason for a period of less than one 
month for sulfasalazine or methotrexate 
and less than two months for hydroxy­
chloroquine, oral gold, aurothioglucose, 
d-penicillamine and azathioprine were 
ignored. When the same drug was pre­
scribed to a patient for more than one 
separate period only the first treatment 
course was included in the analysis. 
Factors influencing continuation of 
DMARD treatment 
The most 'promising' factors emerging 
from our article reviewing risk factors for 
DMARD toxicity were evaluated in the 
present long-term prospective study of 
patients with recently diagnosed RA. 
The variables at baseline were studied 
for their prognostic value regarding tox­
icity as well as efficacy. The courses of 
several variables over time, and at the 
time the ADR occurred, were only stud­
ied in relation to treatment termination 
because of toxicity (Table II). In a subset 
of RA patients serum IgE levels (RIA, 
normal < 150 lU/ml) were determined. 
In only 1 out of 9 patients suffering from 
gold-induced cutaneous reactions an el­
evated serum IgE level (359 lU/ml) was 
found. This patient proved to have had 
an elevated IgE level before institution of 
gold therapy, probably associated with 
his asthmatic lung disease. In 9 control 
patients with comparable age, sex and 
duration of chrysotherapy no elevation of 
IgE was found. In 3 out of 9 untreated RA 
patients IgE levels were increased. The 
relationship between salivary IgA, IgG 
and IgM and occurrence of side effects 
was evaluated in some patients treated 
with sulfasalazine, aurothioglucose and 
hydroxychloroquine. At months 0,2 and 
6 of the second-line antirheumatic treat­
ment saliva samples were collected. RA 
patients visiting our outpatient clinic who 
developed an untoward drug reaction 
during second-line therapy of such sever­
ity that the drug had to be discontinued 
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Table II. Factors influencing continuation of second-line drug treatment tested 
III 
sex 
age 
weight 
use of prednisone 
rheumatoid factor 
disease activity 
-DAS 
-ESR 
- Ritchie articular index 
- number of swollen joints 
- general health 
ANA 
IgA 
IgG 
IEM 
HLA-DR3 
HLA-DR4 
rank order of prescription 
previous toxicity 
I : cohort study; variables present at the start of second-line treatment with respect to treatment termi­
nation because of toxicity and/or lack of efficacy; forward and multivariately (The number of d-peni-
cillamine treated patients was too small for multivariate analysis) 
Π : repeated measurements; comparison of variables during second-line treatment in toxic and non­
toxic patients; forward and multivariately 
III : present at the time the advene reaction occurs; only during chiysotherapy 
were also asked to provide a whole, stim­
ulated saliva specimen, by spitting for a 
10-minute period into a plastic vial 
placed on ice. Stimulation was achieved 
by applying one drop of 2% citric acid to 
the patient's tongue every minute. Saliva 
was collected for at least one and a half 
hour after a meal. To minimize variations 
due to circadian rhythm it was attempted 
to obtain the saliva sample of each pa­
tient at the same time of the day. To avoid 
blood contamination tooth-brushing 
shortly before collection was prohibited. 
To estimate the flow rate each sample 
was weighed and then frozen immedi­
ately at -70 "С until assayed. Statistically 
significant differences between toxic 
(n = 28) and non-toxic patients (n = 25) 
were observed neither in the salivary im­
munoglobulin concentrations nor in the 
production of salivary immunoglobulins 
over time. On the basis of these two pilot 
studies it was decided not to study serum 
IgE and salivary immunoglobulin levels 
in the entire patient group. 
Statistics 
Standard methods of survival analysis 
were used, taking treatment terminations 
because of side effects or lack of efficacy 
as end points. For patients who stopped 
treatment because of remission of the 
disease, death or other reasons and for 
patients who did not reach one of these 
end points the observation time was cen­
sored due to closing data collection at the 
end of 1989. In case of treatment termi­
nation because of toxicity restricted to 
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one particular side effect (cutaneous re-
action; proteinuria; gastrointestinal 
complaints), the observation time was 
censored for other side effects. For pa-
tients who discontinued second-line 
treatment because of side effects with 
only a 'possible' or 'doubtful' causal rela-
tionship (i.e. 'Naranjo score' less than 5) 
the observation time was also censored. 
The relationship between the various 
clinical and laboratory factors (Table II) 
and treatment termination was evaluated 
in three different ways. Firstly, for each 
DMARD Cox's proportional hazards 
(PH) model was applied, with the several 
variables present at the start of DMARD 
treatment as covariates. Factors influ-
encing treatment termination because of 
toxicity or lack of efficacy were selected 
from the multivariate analysis and from a 
forward stepwise procedure ('cohort 
study'). Secondly, the clinical and labo-
ratory data of toxic and non-toxic pa-
tients were compared at each 4-weekly 
interval using t-statistics after transform-
ation to symmetrical distributions (pow-
er transformation)('repeated measure-
ments'). To optimize the data interpola-
tion was carried out. Patients were re-
garded as non-toxic if treated for at least 
one year without treatment termination 
because of side effects. Thirdly, with re-
spect to chrysotherapy, the variables 
were compared at the time ADR oc-
curred in toxic and non-toxic patients 
matched for duration of treatment, sex 
and age. 
RESULTS 
During an observation period of almost 
5 years a DMARD was prescribed 432 
times in 245 patients. In 27 patients no 
second-line drugs were prescribed. The 
numbers of times the various DMARDs 
were administered were: hydroxychloro-
quine 135, sulfasalazine 118, aurothio-
glucose 96, d-penicillamine 34, metho-
trexate 18, azathioprine 18 and oral gold 
13. Because of the small number of pre-
scriptions of oral gold, methotrexate and 
azathioprine, statistical analysis with the 
factors tabulated in table II as covariates 
could be done only for hydroxychloro-
quine, sulfasalazine, aurothioglucose 
and d-penicillamine. 
We previously reported the 'comparative 
drug survivals' of hydroxychloroquine, 
sulfasalazine, aurothioglucose and d-
penicillamine. 
Risk factors for treatment discontinua-
tion because of toxicity 
Aurothioglucose. Of all the variables 
(Table II) present at the start of second-
line therapy, only advanced age, female 
sex, increased IgA, and presence of 
HLA-DR3 showed a statistically signifi-
cant decrease of the 'gold survival.' The 
magnitude and direction of these 'risk 
factors' can be expressed in so-called 
'conditional relative risks' (CRR). A 
CRR reflects the relative risk of occur-
rence of an event (e.g. treatment discon-
tinuation because of toxicity) during a 
certain short period of time (e.g. one 
month) given an equal event-free period 
of treatment (Table III). 
In the comparison of the several vari-
ables in toxic and non-toxic patients at 
each 4-weekly interval during chrysothe-
rapy no significant differences could be 
found. 
With respect to discontinuation because 
of sulfasalazine-induced toxicity ad-
vanced age and high rank order of pre-
scription appear factors of increased 
risk. Using 'repeated measurements' no 
risk factors for sulfasalazine toxicity 
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could be detected. creased by a high rank order of pre-
No factors influencing the discontinua- scription.lt is of interest that discontinu-
tion rate of hydroxychloroquine and d- ation of hydroxychloroquine treatment 
penicillamine therapy because of ADR because of lack of efficacy occurred re-
were observed, either in the 'cohort markably less frequently among HLA-
study,' or using 'repeated measure- DR3 positive than among HLA-DR3 
ments.' negative patients. The CRRs and the 
corresponding 95% confidence intervals 
Factors influencing treatment termina· are listed in table III. 
tion because of insufficient therapeutic 
response 
With regard to treatment termination be- DISCUSSION 
cause of lack of efficacy the 'survivals' of 
hydroxychloroquine, sulfasalazine and Upon reviewing the literature regarding 
d-penicillamine were all decreased by risk factors for DMARD toxicity little 
high initial disease activity. The survival agreement was found. This may be ex-
period of sulfasalazine was also de- plained by the retrospective design of 
Table III. Conditional relative risks (CRR) and 95% confidence intervals 
risk factor 
treatment discontinuation because of 
aurothioglucose 
age (per decade) 
sex (Temale vs male) 
ITLA-DR3 (present vs absent) 
sulfasalazine 
age (per decade) 
rank order (per prescription) 
forward 
toxicity ('Naranjo score' 
1.30 (1.14 
7.61 (1.43 
5.10 (1.01 
2.12(1.09 
г 5) 
-1.48)' 
-40.61):* 
-26.31)* 
-4.10)' 
multivariate 
3.37(1.05-10.75)' 
5.81(1.38-24.53)/ 
4.22(1.27-10.75) 
2.10(1.48-2.99)' 
treatment discontinuation because of lack of tfflcacy 
sulfasalazine 
DAS (per DAS point) 
rank order (per prescription) 
hydroxycbloroqulne 
DAS (per DAS point) 
HLA-DR3 (present vs absent) 
d-ptnlcl!lamlne 
DAS (per DAS point) 
1.64 (1.06 • 
1.72(1.01· 
1.42(1.11-
0.39(0.18-
3.48 (1.01 • 
2.53): 
• 2.95) 
•im: 
0.82) 
12.68)' 
2.19(1.28-3.76):* 
2.91(1.06-7.84) 
0.27(0.10-0.71)" 
t;p<0.Q5; :p<0.01 
I' applies only to cutaneous advene reactions 
: applies only to proteinuria 
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most studies, the wide variation in side 
effects encountered, the relatively small 
sample size, and differences in patient 
groups studied. Furthermore, most stud-
ies lack adequate criteria for ascertain-
ing adverse drug reactions. The most 
'promising' factors emerging from our 
review article were evaluated prospec-
tively in the present long-term study of 
patients with recently diagnosed RA. 
Based on the unrewarding results of the 
pilot studies concerning serum IgE levels 
and salivary immunoglobulins in relation 
to occurrence of side effects we decided 
not to study these variables in the entire 
patient group. 
In this long-term prospective study ADR 
occurring during second-line antirheu-
matic treatment were mvestigated in de-
tail. Causality assessment ('Naranjo 
score') was done in order to minimize 
misclassifications. Differences between 
toxic and non-toxic patients in various 
clinical and laboratory variables (Table 
II), present at the start of the second-line 
treatment, the course of these variables 
over time, and variables present at the 
time of side effects were studied. 
In accordance with the literature HLA-
DR3 appeared a risk factor for auro-
thioglucose toxicity, proteinuria in par-
ticular. In earlier studies ' a decreased 
tolerance for intramuscular gold therapy 
in the elderly was reported. A more re-
cent study failed to show such an in-
creased risk. With respect to sulfasala-
zine Pullar et al. reported a higher 
drop-out rate from therapy because of 
upper gastrointestinal symptoms in el-
derly patients. In our study increasing 
age appeared to predispose to discon-
tinuation of chrysothcrapy and treatment 
with sulfasalazine. The drop-out rate due 
to gold toxicity, in particular due to cuta-
neous reactions, was higher among fe-
male than among male patients. Selective 
IgA deficiency has been associated with 
toxicity during second-l ine treat-
ment.20, Low serum IgA concentra-
tions have also been shown to correlate 
11 
with toxic reactions to aurothioglucose 
and azathioprine. However, the associ-
ation with gold-induced toxicity was not 
confirmed by some investigators, ' 
and only partly by Ostuni et al. In the 
present study decreased serum IgA lev-
els could not be related to gold-induced 
toxicity, either. On the contrary, a re-
lationship between increased serum IgA 
levels and occurrence of proteinuria was 
observed. 
In order to study factors influencing effi-
cacy of second-line antirheumatic drugs, 
treatment discontinuations because of 
insufficient response were evaluated. 
It is hard to presage what influence initial 
disease activity may have on the discon-
tinuation rate of DMARDs because of 
insufficient therapeutic response. More 
active disease might be more resistant to 
therapy, but may also have a greater ca-
pacity for amelioration. We found that 
initial active disease predisposes to dis-
continuation of treatment with hydroxy-
chloroquine, sulfasalazine or d-penicilla-
mine because of lack of efficacy. For sul-
fasalazine the rank order of prescription 
appeared also to be of importance with 
respect to efficacy. This maybe of impor-
tance for the interpretation and compar-
ison of clinical trials in the literature. 
Recently, Situnayake and McConkey^ 
reported that with respect to sulfasala-
zine therapy responders were signifi-
cantly younger than nonrespondcrs and 
that disease duration in responders was 
significantly shorter than in nonrcspon-
ders. This may be in accordance with our 
results since the rank order of prescrip-
tion is related to the duration of disease. 
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The relationship between age and 
respondership they showed may be ex­
plained by an increased toxicity in the 
elderly, since treatment duration longer 
than six months was defined as one of the 
criteria of respondership and withdrawal 
because of side effects of sulfasalazine 
mostly occurs during the first three 
months of treatment. ' 
Of interest is that discontinuation of 
hydroxychloroquine because of lack of 
efficacy occurred less frequently in 
HLA-DR3 positive than in HLA-DR3 
negative patients as similar observations 
have been made for chrysotherapy. The 
fact that we could not confirm the favor­
able response to chrysotherapy in HLA-
DR3 positive patients may be explained 
by our methodology: only treatment dis­
continuation because of lack of sufficient 
therapeutic response was taken as an end 
point in the survival analysis. Therefore, 
discrimination between moderate and 
excellent responders was not possible. In 
the literature a relationship was observed 
only between excellent respondership 
and HLA-DR3. 
Conclusion. Factors influencing the con­
tinuation of second-line antirheumatic 
drugs were prospectively studied in a 
consecutive series of patients with re­
cently diagnosed rheumatoid arthritis. A 
statistically significant influence of some 
variables present at the start of DMARD 
treatment on the 'drug survival' was ob­
served. However, the magnitude of these 
factors is r a t h e r low and the 
interindividual variability rather large. 
Therefore, the clinical applicability of 
these factors with regard to drug policy 
is limited. However, these risk factors 
and the factors concerning efficacy may 
be of importance in the interpretation 
and the comparison of clinical trials. 
During treatment no differences in the 
course of the variables over time between 
toxic and non-toxic patients were ob­
served. 
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ABSTRACT 
The disease rheumatoid arthritis itself is often assumed to be a risk factor for the 
occurrence of adverse drug reactions during sulfasalazine therapy. A meta-analysis 
comparing treatment termination because of toxicity among rheumatoid arthritis, 
inflammatory bowel disease and seronegative spondylarthropathy patients was con-
ducted. It is shown that rheumatoid arthritis itself does not appear to predispose to 
treatment discontinuation because of adverse reactions. Differences found in the 
incidence of side effects among the various disease groups can probably be explained 
by patient selection, particularly with respect to age, proportion treated for the first 
time with sulfasalazine, and dosage used. 
Disease Modifying Anti-Rheumatic Drugs (DMARDs) play a key role in 
the treatment of Rheumatoid Arthritis 
(RA). An important restriction in apply-
ing DMARDs is that drug treatment 
must be abandoned in a high percentage 
of patients because of adverse drug reac-
tions. It is often proposed that RA itself 
appears to predispose to drug toxicity. 
RA patients show a much higher fre-
quency of allergic reactions to d-peni-
cillamine and, in addition, the side effect 
profile differs from that of patients 
treated for cystinuria or Wilson's dis-
1 2 « 
ease. ' The retinal damage caused by 
chloroquine appears to be predisposed 
by the effect of RA on the retina. An 
increased susceptibility in patients with 
RA to acute methotrexate pneumonitis 
has been suggested. Cases of granulo-
cytopenia and rashes are disproportion-
ally more often observed in rheumatic 
patients treated with levamisole than in 
patients treated for other diseases. ' 
Sulfasalazine (SASP) was introduced in 
1942 by Nanna Svartz for the treatment 
of ulcerative colitis and rheumatoid ar-
thritis. After the unfavorable results of 
the study published by Sinclair and 
Duthie, for the next three decades, the 
drug was restricted to patients with in-
flammatory bowel disease (IBD). Then, 
interest in SASP as a second-line anti-
rheumatic drug was renewed. Its efficacy 
was proved by several controlled studies. 
More recently it was suggested that 
SASP might be useful in the treatment of 
seronegative spondylarthropathics 
(SSpA), including ankylosing spondyli-
tis, reactive arthritis and psoriatic arthri-
tis. It is often assumed that the incidence 
of adverse drug reactions, particularly 
leukopenia, is higher among patients 
with RA than among patients suffering 
from IBD. However, the exact incidence 
of side effects in both RA and IBD has 
not been established. 
Meta-analysis is a strategy for statisti-
cally combining and analyzing the results 
of previous reports. We conducted a 
meta-analysis to compare early dropout 
because of SASP-induced toxicity for the 
various diseases mentioned. 
MATERIALS AND METHODS 
Our meta-analysis methodology was 
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Table I. Designs and characteristics of the studies included 
SSpA IBD RA 
number of studies 
year of publication (SD) 
number of participating 
centres 1 
2 4 
5 
% blind 
duration of follow-up 
weeks, mean (SD) 
shortest interval between 
two control visits 
mean, weeks (SD) 
quality assessment 
mean score (SD) 
number of patients 
mean number (SD) 
duration of disease 
mean, years (SD) 
% female (SD) 
age 
mean, years (SD) 
% maintenance treatment 
maximum dose administered 
mean, mg (SD) 
% patients (SD) treated 
for the first time with 
sulfasalazine 
enteric coating mentioned 
(% studies) 
concomitant drug treatment 
NSAIDs 
(% studies allowed) 
corticosteroids 
(% studies allowed) 
9 
'87.6(1.9) 
6 
2 
1 
55.6 
38.2(28.5) 
6.7(4.1) 
2.4(0.3) 
28.3 (12.2) 
8.1 (3.8) 
24.7(9.6) 
33.7(7.7) 
11.1 
2778 (833) 
100(0) 
55.6 
100 
0 
23 
'86.1 (3.2) 
7 
9 
7 
82.6 
26.5 (24.6) 
5.6(4.9) 
2.3(0.4) 
48.6 (45.1) 
5.6(3.9) 
47.8(11.3) 
40.1 (63) 
47.8 
3295 (1333) 
29.8 (32.8) 
30.4 
0 
4.3 
17 
'85.8 (3.1) 
8 
5 
4 
35.3 
33.5 (21.8) 
4.8 (2.9) 
2.4(0.4) 
41.5 (24.0) 
8.6(3.6) 
73.7(143) 
54.2(2.6) 
0 
2441 (556) 
96.8 (7.3) 
763 
100 
47.1 
NS 
NS 
·* 
NS 
NS 
NS 
NS 
NS 
·** 
*** 
** 
* 
· · · 
• 
· · · 
• a* 
t 
x
1 
x
2 
t 
t 
t 
t 
t 
t 
t 
x
2 
t 
t 
x
2 
x
2 
x
2 
Abbrevialions: f: analysis of variance; χ : chi-square; *: p<0.05; ·*: p<0.01; ·*· :ρ<0.001 
ρ: overall statistical comparison 
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Meta-analysis of sulfasalazine toxicity 
based on the 'framework' of generic is-
sues in meta-analysis described by Sacks 
et al,11 L'Abbé et al,12 and Naylor.13 It 
consisted of six steps: a. protocol devel-
opment including defining study objec-
tives; b. determination of study inclusion 
and exclusion criteria; с literature 
search; d. assessment of study quality; e. 
data abstraction; f. implementing the me­
ta-analysis computation, including sensi­
tivity analysis. 
Study objectives. The major objective of 
our meta-analysis was to find out 
whether RA patients are more suscepti­
ble to treatment discontinuation because 
of side effects during sulfasalazine ther­
apy than patients with inflammatory 
bowel disease or seronegative spondyl-
arthropathies. Furthermore, we in­
tended to study the side effect profile of 
sulfasalazine in the different disease 
groups. 
Study inclusion and exclusion criteria. 
All reports dealing with sulfasalazine 
treatment for SSpA, RA or IBD written 
in English, French or German were in­
cluded in the data pool. 
Studies with less than 10 patients treated 
with SASP were excluded, as were stud­
ies dealing with juvenile rheumatoid ar­
thritis and narrative reviews or critiques, 
'double' publications, abstracts and 'let­
ters to the editor.' 
Literature search. A computerized lit­
erature search was conducted using the 
National Library of Medicine (MED­
LINE ) data base. Publications starting 
from 1980 fitting in with the search terms 
'clinical trial,' in combination with 'sali-
cylazosulfapyridine' and 'rheumatoid ar­
thritis,' 'psoriatic arthritis,' 'ankylosing 
spondylitis' or 'inflammatory bowel 
disease' were selected. Studies were also 
retrieved from a personal data base build 
up during many years of personal interest 
in SASP. 
Quality assessment. Each study was 
evaluated independently by two observ­
ers (MW/PvR) according to the qualita­
tive criteria used by Clark et al. : (1) 
Were the study patients adequately de­
scribed? In particular, is the proportion 
of patients treated with SASP for the first 
time known? (2) Is the drug therapy ad­
equately described, especially with re­
spect to the enteric coating of the SASP 
tablets, the gradual increase of the dose 
and 'really* administered dose? (3) Were 
all of the patients who entered the study 
accounted for in the results? (4) Were all 
clinically relevant outcomes reported? In 
particular, with regard to the time of 
drop-out. Since open studies were also 
'enrolled' in this meta-analysis the quali­
tative criteria regarding proper blinding, 
randomization and statistical and/or 
clinical significance were left out. For the 
four qualitative criteria mentioned 
above, each publication was rated a '3', if 
the criterion was fully met, a '2' if it was 
only partly met and a '1 ' in case of not 
mentioning the subject at all. The 
Pearson's correlation coefficient be­
tween the scores of the two observers was 
0.74 (p< 0.0001). In case of non-agree­
ment a consensus was sought in open 
discussion. The mean score of the four 
items was then computed. 
Data collection. Data collection was con­
ducted independently by two investiga­
tors (MW/PvR) using a data abstract 
form. 
Meta-analysis/statistics. For side effects 
the method for pooling discrete data 
used was the log(odds-ratio) (log (odds) 
= In (p/(l-p)), with ρ the proportion 
withdrawn)). Residuals were weighted 
according to sample size. The influences 
of various factors on the proportion 
withdrawn because of toxicity were stud-
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ied in a linear regression model on 
'log(odds).' 
RESULTS 
Forty-nine studies were eligible for meta-
analysis. Nine studies concerning 
15 2'? 
SSpA ' included six studies dealing 
with ankylosing spondylitis, two with re-
active arthritis and one with psoriatic ar-
thritis. Seventeen studies dealt with 
RA. " The IBD group was composed 
of four trials in which sulfasalazine was 
administered to patients with Crohn's 
disease, 18 trials of patients with ulcera-
tive colitis and one study in which treat-
ment was given for both diseases. 
Seventy-four studies retrieved from the 
Medline search procedure were ex-
cluded because of insufficient numbers 
of patients or the fact that they either 
were narrative reviews, double publica-
tions, abstracts or letters to the editor or 
concerned juvenile rheumatoid arthri-
tis. " One publication was not avail-
able in the Netherlands. 
The designs of these studies and some 
characteristics of the patients are listed 
in table I. As expected, a preponderance 
of female sex was observed in the studies 
dealing with RA. Furthermore, signifi-
cant differences between the three dis-
ease groups were found in mean age, 
maximal dose administered, and propor-
tion of patients treated for the first time 
with SASP. No differences in quality as-
sessment, duration of follow-up and 
number of patients could be proved. The 
small proportion (29.8%) of IBD pa-
tients treated with sulfasalazine for the 
first time is noteworthy. 
In total, 184 'patient years' of SASP treat-
ment were studied among SSpA patients, 
713 years among IBD, and 552 years 
among RA patients. The profiles of the 
Adverse Drug Reactions (ADR) leading 
to withdrawal are presented in table II. 
Table II. Side effect profiles of adveise drug reactions leading to withdrawal 
SSpA IBD RA 
% gastrointestinal 
% cutaneous reactions 
% headache 
% others: 
% haematological 
% depressive feelings 
% elevation of transaminases 
% 'dizziness' 
% others 
47 
20 
15 
18 
9 
3 
6 
0 
0 
42 
37 
8 
13 
0 
7 
0 
0 
6 
49 
25 
6 
20 
6 
1 
2 
3 
8 
X2:NS 
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Table III. The Relative Risks (RR) of treatment termination because of toxicity 
without correction for confounding factors: 
RR (95% CI) 
RAvsIBD RAvsSSpA 
total period of follow-up 
initial 3 months of treatment 
4.35(2.82-6.76)**· 1.55 (1.07-2.24)* 
2.72(1.42-5.21)** 1.42(0.77-2.63) 
after correction for age, proportion first treated and dose: 
total period of follow-up 
initial 3 months of treatment 
0.91 (0.18-4.67) 0.49 (0.23-1.03) 
0.08(0.01-1.13) 0.12(0.05-0.29)·· 
· : P<0.05; · · : P<0.01; ***: P<0.0001 
No statistically significant differences in 
side effect profiles could be established. 
It is of interest that among the SSpA 
patients, the group with the fewest 'pa-
tient years,' hematological reactions and 
elevations of transaminases were ob-
served most frequently, while in the 
group with the largest number of'patient 
years' these ADR were never encoun-
tered. 
In order to compare the proportions of 
patients withdrawn from the study be-
cause of toxicity the log(odds) was com-
puted within each disease group. A sta-
tistically significant difference between 
the three groups was found (p< 0.0001, 
linear regression model, weighted for 
sample size). The Relative Risk (RR) to 
discontinue SASP treatment in RA pa-
tients compared with IBD patients was 
435 (p< 0.0001). The RR comparing 
RA with SSpA is 1.55 (p<0.05). Re-
stricted to discontinuation of treatment 
during the first three months of the study 
the relative risks are 2.72 (p < 0.01) and 
1.42 (NS), respectively. In computing the 
relative risks no account was taken of 
confounding factors. We studied the in-
fluences of possible confounding factors 
such as sex, age, maximal dose adminis-
tered, enteric coating of tablets, study 
design (blindness), duration of follow-
up, proportion of patients treated for the 
first time with SASP and kind of therapy 
(maintenance vs treatment of active dis-
ease) in a stepwise backward linear re-
gression model. Only- in order of impor-
tance - age, proportion of patients 
treated for the first time, and maximal 
dose administered proved to be of signif-
icant influence on the proportion with-
drawn. Advanced age, a large proportion 
of patients never treated with SASP be-
fore and a high dosage increase the per-
centage of patients withdrawn because of 
side effects. 
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Figure 1. Mean age of patients in each study against the proportion withdrawn because of adverse drug 
reactions 
In figure 1 the mean age of patients in 
each report is plotted against the per­
centage of patients discontinuing treat­
ment because of toxicity. Parallel regres­
sion lines are computed for each disease 
group. It is shown that the regression line 
through the studies concerning RA is a 
continuation of that of studies dealing 
with SSpA, illustrating the influence of 
age as a confounding factor on treatment 
discontinuation. The regression line of 
the IBD patients is close to the line 
through the studies concerning RA and 
SSpA, indicating that besides age other 
confounding factors are responsible for 
the differences found in proportion of 
treatment termination. 
After correction for the three major con­
founding factors the differences in the 
proportions of treatment termination be­
cause of toxicity during the total study 
vanished. With regard to the initial three 
months no statistically significant differ­
ence between RA and IBD patients was 
found, either. A significantly smaller pro­
portion discontinuing SASP treatment in 
the first three months was observed 
among the RA than among the SSpA 
patients (Table III). 
SENSITIVITY ANALYSIS 
The influence of study quality on the re­
sults of the meta-analysis was investi­
gated by comparing the results as pre­
sented above with the outcome of the 
analysis only of studies of a 'fair' quality 
(mean quality score above 2; see 'quality 
assessment'). No substantive changes in 
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log(odds-ratios) or levels of statistical 
significance were observed. 
DISCUSSION 
It is assumed that the incidence of ad-
verse drug reactions to SASP, particu-
larly the hematological ones, is higher 
among RA than among IBD and SSpA 
patients. Concomitant use of NSAIDs by 
arthritic patients, increased bowel motil-
ity in IBD patients and differences in 
genetically determined immunological 
response to drugs between these disease 
groups are often mentioned as possible 
explanations. 
A meta-analysis was carried out compar-
ing the proportions withdrawn from 
SASP treatment because of toxicity 
among RA, IBD and SSpA patients. Dis-
regarding confounding factors, the risk 
of having to discontinue SASP treatment 
was significantly greater among RA pa-
tients than among patients suffering from 
the other two disease entities. It is evi-
dent from our analysis that age was the 
most important confounding factor. This 
is in accordance with the literature, as a 
higher drop-out rate from therapy be-
cause of upper gastrointestinal symp-
toms in elderly patients has been report-
ed.137'138 
The second important confounding fac-
tor proved to be earlier treatment with 
sulfasalazine: 70% of the IBD patients 
had previously been treated with sulfa-
salazine. As side effects of sulfasalazine 
mostly occur during the first three 
months of treatment ' a frank patient 
selection with regard to sulfasalazine tol-
erance must be assumed. The fact that 
none of the IBD patients discontinued 
treatment because of hematological re-
actions or elevation of transaminases 
(table II) is probably also a reflection of 
this selection. 
Adverse reactions to sulfasalazine, par-
ticularly those of gastrointestinal origin, 
have been related to daily doses in IBD 
and RA patients.32,52,137 It is therefore 
not surprising that the maximal dose ad-
ministered also emerged as a confoun-
der. 
After correction for these three confoun-
ding factors the differences in drop-out 
among the three disease groups van-
ished. With respect to the initial three 
months RA patients showed even less 
treatment discontinuation than SSpA 
patients. 
Meta-analysis has limitations and there-
fore results should be interpreted with 
due caution, especially, as it is impossible 
to recognize, investigate and correct for 
all confounding factors (affecting the 
study outcome), since one depends on 
the information presented in the individ-
ual studies. 
Conclusions On account of this study 
the assumption that RA itself predis-
poses to adverse drug reactions leading 
to withdrawal does not appear to be cor-
rect. Differences in incidence of adverse 
drug reactions found among the three 
disease groups may be explained by pa-
tient selection. 
Furthermore, it is shown that the side 
effect profiles in the three diseases stud-
ied are not different. 
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chapter 10 
SUMMARY AND CONCLUSIONS 

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and second-line 
antirheumatic drugs - also called Disease 
Modifying Anti-Rheumatic Drugs 
(DMARDs) - play a key role in the treat-
ment of patients with rheumatoid arthri-
tis (RA). An important restriction in ap-
plying DMARDs is that a substantial 
proportion of patients have to be taken 
off these drugs because of lack of efficacy 
or major side effects. 
In the present thesis special attention is 
paid to the occurrence and characteris-
tics of side effects during second-line 
treatment. In addition, factors influenc-
ing treatment discontinuation are stud-
ied. 
In chapter 1 the incidence of RA, some 
clinical characteristics and the impor-
tance of second-line drug treatment are 
described. In addition, some features of 
adverse drug reactions and a method for 
causality assessment are discussed. 
A review of the literature regarding risk 
factors for DMARD toxicity is presented 
in chapter 2. It can be concluded that 
there is little agreement in the literature 
with respect to risk factors for DMARD 
toxicity. However, some findings of inter-
est may emerge from this review. Ex-
ceeding the recommended daily doses of 
hydroxychloroquine and chloroquine 
appears to be a principal risk factor for 
developing retinopathy. Low sulfoxida-
tion capacity, smoking, IgA deficiency, 
eosinophilia, and HLA-DR3 predispose 
to parenteral gold toxicity. Sulfoxidation 
status, starting dose, HLA-DR3 pheno-
type, and age are factors influencing the 
development of side effects of d-peni-
cillamine. Previous chrysotherapy or 
gold toxicity probably do not affect the 
risk of d-penicillamine toxicity. Acctyl-
atorship, age, and dose appear to influ-
ence sulfasalazine toxicity, especially for 
minor side effects. Most of the common 
side effects of MTX respond to dose 
adjustment. Previous azathioprinc treat-
ment may increase the risk of liver cell 
necrosis from cyclophosphamide. The 
sensitivity and specificity of these risk 
factors in predicting the occurrence of 
adverse drug reactions in a given patient 
are low; therefore, routine clinical and 
laboratory monitoring is still necessary. 
In chapter 3 a relatively harmless drug 
reaction is described: the occurrence of 
subclinical hemolysis during sulfasa-
lazine treatment. Hemolysis should be 
seriously considered as a cause of the 
relative lack of increase of hemoglobin 
often observed in RA patients success-
fully treated with sulfasalazine. Although 
the clinical significance of the induced 
hemolysis is limited, it makes hemoglo-
bin, a commonly used disease activity 
parameter in RA, unreliable for the eval-
uation of sulfasalazine treatment. 
In chapter 4 two other examples of ad-
verse drug reactions during second-line 
treatment are presented. Firstly, the oc-
currence of a generalized urticarial erup-
tion during azathioprinc treatment, and 
secondly, relapsing thrombocytopenia 
during parenteral gold, sulfasalazine and 
hydroxychloroquine treatment. In the 
patient with the cutaneous reaction the 
low scrum IgA levels probably reflect an 
increased susceptibility to untoward 
drug reactions. In the patient with the 
relapsing thrombocytopenia a genetical-
ly determined HLA-DR3 and B8 aber-
rant immunological response to stimuli 
such as certain second-line drugs may be 
responsible. 
Starting January 1985 all consecutive pa-
tients attending the Nijmegen or the 
Groningen University Hospital with re-
cent onset ( < 1 year) rheumatoid arthri-
tis who had not previously been treated 
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were asked to participate in a long-term 
prospective open study in which treat-
ment by different rheumatologists was 
monitored by research nurses. Fourteen 
out of 47 patients who started parenteral 
gold treatment developed a dermatitis of 
such severity that the dose had to be 
reduced or chrysotherapy discontinued. 
In all these cases a dermatologist was 
consulted. A close resemblance to con-
tact dermatitis was noticed in three pa-
tients. It is striking that the patients who 
developed a gold-induced contact-dcr-
matitis-likc rash were all female, that two 
of these were previously sensitized to 
nickel and that the time needed to re-
cover after discontinuation of chrysothe-
rapy was significantly shorter in these 
patients compared with the patients with 
a 'gold dermatitis' diagnosed by exclu-
sion (2-4 weeks versus 2-8 months). It is 
assumed that chrysotherapy can be held 
responsible for the exacerbation of the 
contact hypersensitivity to nickel (chap-
ter 5). 
Efficacy and toxicity of antirheumatic 
drugs are usually studied in relatively 
short-term clinical trials, concerning 
small numbers of selected patients. 
Therefore, some doubt about conclu-
sions for 'everyday practice' based on 
such 'experiments' under well-defined, 
and rather ideal trial conditions seems 
justified. The study of long-term follow-
up of NSAIDs in 'everyday practice' 
(chapter 6) showed that a small number 
of NSAIDs are judged appropriate by 
the patient and attending physician to 
treat rheumatoid arthritis for at least a 
few years in addition to second-line 
agents. A survival analysis was done in 
which treatment terminations because of 
side effects and of insufficient therapeu-
tic effect were used as index causes. Cu-
mulative drug 'survival' of indomethacin 
with treatment termination because of 
toxicity as end point was significantly less 
compared with naproxen and diclofenac. 
No significant difference with termina-
tion because of lack of efficacy as index 
cause was observed and no influence of 
sex or age on the drug 'survival' could be 
established. Furthermore, it was shown 
that adverse drug reactions of such sever-
ity that the NSAID treatment had to be 
discontinued occurred mostly in the first 
few weeks of treatment, although drop-
out because of untoward drug reactions 
was also observed in later phases, con-
firming the shortcomings of short-term 
studies. 
The administration time of second-line 
antirheumatic drugs was prospectively 
studied in 245 patients (chapter 7). The 
estimated cumulative drug 'survival' of 
aurothioglucose with treatment termina-
tion because of toxicity was significantly 
less compared with hydroxychloroquine. 
With regard to lack of efficacy as index 
cause, the administration time of hy-
droxychloroquine was significantly less 
than that of either aurothioglucose or 
sulfasalazine. Furthermore, it was shown 
that treatment discontinuation because 
of adverse drug reactions during hy-
droxychloroquine, sulfasalazine and d-
penicillamine therapy is restricted to the 
first year of treatment, while discontinu-
ation of chrysotherapy because of toxic-
ity is extended over a much longer pe-
riod. Discontinuation because of lack of 
efficacy goes on for about 2 years with all 
four DMARDs. 
In chapter 8 clinical and laboratory vari-
ables influencing the continuation of the 
second-line antirheumatic drug treat-
ment described in chapter 7 were evalu-
ated. A statistically significant influence 
of age, sex, serum IgA and HLA-DR3 on 
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the discontinuation rate of chrysothera-
py because of toxicity was observed. The 
continuation of sulfasalazine was dimin-
ished by advanced age and high rank 
order of prescription. With respect to 
efficacy, high initial disease activity ap-
peared to predispose to treatment termi-
nation of hydroxychloroquine, sulfasala-
zine and d-pcnicillamine because of in-
sufficient therapeutic response. Further-
more an influence of the rank order of 
prescription on discontinuation of sul-
fasalazine therapy because of lack of ef-
ficacy was found. Of interest is that dis-
continuation of hydroxychloroquine the-
rapy because of lack of efficacy occurred 
less frequently in HLA-DR3 positive 
than in HLA-DR3 negative patients. Al-
though these prognostic factors are of 
secondary importance in clinical prac-
tice, they may be of significance in the 
interpretation and comparison of clinical 
trials. During second-line treatment no 
differences in the course of the variables 
over lime between toxic and non-toxic 
patients could be observed. 
The disease rheumatoid arthritis itself is 
often assumed to be a risk factor for the 
occurrence of adverse drug reactions 
during sulfasalazine therapy. The results 
of a meta-analysis comparing treatment 
termination because of toxicity among 
rheumatoid arthritis, inflammatory 
bowel disease and seronegative spondyl-
arthropathy patients is described in 
chapter 9. Rheumatoid arthritis docs not 
appear to predispose to treatment termi-
nation because of adverse reactions. Dif-
ferences found in the incidence of side 
effects among the various disease groups 
can probably be explained by patient se-
lection, particularly with respect to age, 
proportion treated for the first time with 
sulfasalazine and dosage. 
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Reumatoïde Artritis (RA) is een ziekte, 
die zich kenmerkt door chronische ge-
wrichtsontstekingen. Naast de gewricht-
en kunnen ook bloedvaten, hart en long-
en zijn aangedaan. De ziekte treft 1 à 2% 
van de bevolking en komt meer bij vrou-
wen dan bij mannen voor. De oorzaak 
van reumatoïde artritis is onbekend. 
Langdurige gewrichtsontsteking, 'artri-
tis,' kan leiden tot irreversibele ge-
wrichtsschade en daardoor tot invalidi-
teit. Bij de behandeling neemt de medi-
camenteuze therapie een belangrijke 
plaats in. Daarnaast zijn fysiotherapie, 
ergotherapie, maatschappelijke begelei-
ding en eventuele orthopedische behan-
deling van belang. De geneesmiddelen, 
welke gebruikt worden, kunnen onder-
verdeeld worden in twee groepen (tabel 
I). De zogenaamde niet steroide analge-
tische anti-inflammatoire geneesmiddel-
en (NSAID's) vormen de eerste groep. 
Zoals de naam al zegt gaat het hier om 
stoffen met een pijnstillende en ontste-
kingsremmende werking, die niet ver-
want zijn aan bijnierschorshormonen. 
De tweede groep geneesmiddelen wordt 
tweede-lij ns antireumatica of ook wel 
disease modifying anti-rheumatic drugs 
(DMARD's) genoemd. Meestal wordt 
een medicament uit de ene groep naast 
een geneesmiddel uit de andere groep 
voorgeschreven. Van enkele DMARD's 
is, in tegenstelling tot de NSAID's aan-
ncmelijk gemaakt, dat ze het ontstaan 
van blijvende gewrichtsschade kunnen 
remmen. Soms kan zelfs de ziekte door 
deze laatste middelen 'tot staan' worden 
gebracht. Een beperking in het gebruik 
van DMARD's vormt het feit, dat tot 
70% van de patiënten binnen twee jaar 
de therapie moet staken wegens het op-
treden van bijwerkingen of het uitblijven 
van effect. Een ander nadeel is dat het 
enkele maanden duurt voordat van een 
nieuw gestart DMARD de effectiviteit 
beoordeeld kan worden. Mocht het mid-
del na die tijd ineffectief blijken, dan 
moet een ander DMARD geprobeerd 
worden, hetgeen tot gevolg heeft, dat de 
patiënt gedurende vele maanden inade-
quaat behandeld wordt, wat dan weer tot 
irreversibele gewrichtsschade kan 
leiden. Ook als van DMARD gewisseld 
moet worden ten gevolge van bijwerking-
en, kan zo'n periode van kans op verdere 
gewrichtsschade volgen. Kennis van 
voorspellende factoren voor effectiviteit 
en toxiciteit van DMARD's zou er toe 
kunnen bijdragen het optreden van der-
gelijke periodes te beperken of de duur 
ervan te bekorten. In de literatuur zijn 
slechts enkele effectiviteitsvoorspellen-
de factoren beschreven. Deze blijken 
echter niet van praktische betekenis. 
Daarentegen worden vele risicofactoren 
voor het ontstaan van bijwerkingen tij-
dens tweede-lijns therapie genoemd. 
Een systematisch literatuur overzicht van 
deze laatste factoren wordt in hoofdstuk 
2 van dit proefschrift gegeven. Bij het 
bezien van die literatuur valt de geringe 
overeenstemming tussen de verschillen-
de publikaties op. Mogelijk dat de stu-
dieopzet, het brede spectrum aan bijwer-
kingen, de relatief kleine onderzoeks-
aantallen en verschillen in onderzoeks-
populaties, bijvoorbeeld wat betreft ziek-
tcactiviteit, hieraan debet zijn. Toch is er 
enige overeenstemming tussen de ver-
schillende onderzoeken. Zo speelt bij de 
behandeling met chloroquine en hy-
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Tabel I. Voorbeelden van geneesmiddelen gebruikt voor de behandeling van reumatoïde artritis 
NSAID's 
ibuprofen 
indomethacine 
diclofenac 
ketoprofen 
naproxen 
Piroxicam 
droxychloroquine de dagelijkse dosis 
een belangrijke rol bij het ontstaan van 
netvliesafwijkingen en zijn bepaalde er-
felijke factoren (een lage sulfoxidatie ca-
paciteit, het HLA-DR3 fenotype), even-
als de afwezigheid van een bepaald 'af-
weer-eiwit' (Immunoglobuline A: IgA) 
en de aanwezigheid van bepaalde witte 
bloedcellen (eosinophielen) in te grote 
mate, geassocieerd met een verhoogd 
risico tijdens therapie met goudinjecties 
(aurothioglucose). Wat betreft het op-
treden van bijwerkingen tijdens d-peni-
cillamine therapie zijn dezelfde boven-
genoemde erfelijke factoren evenals de 
startdosis en de leeftijd van belang. Eer-
der doorgemaakte bijwerkingen op goud 
zijn niet van invloed. De erfelijk bepaal-
de afbraak van het medicament (de ace-
tylering), leeftijd en dagdosis vormen de 
belangrijkste risicofactoren voor sulfa-
salazinetherapie, vooral wat betreft de 
relatief lichte bijwerkingen, zoals misse-
lijkheid en braken. De voorspellende 
waarde van deze risicofactoren tijdens 
individuele patiëntenzorg is echter laag, 
zodat de gebruikelijke monitoring (met 
name bloedcontroles) nog steeds nood-
zakelijk blijft. 
Onder het begrip 'bijwerking* wordt ver-
staan ieder onbedoeld effect, veroor-
zaakt door het gebruik van een genees-
middel in therapeutische dosering. Bij-
DMARD's (tweede-lijns middelen) 
auranofin (goudtabletten) 
aurothioglucose (goudinjecties) 
azathioprine 
d-penicillamine 
hydroxychloroquine (antimalaria-middelen) 
methotrexaat 
sulfasalazine 
werkingen hoeven dus niet altijd scha-
delijk te zijn. In hoofdstuk 3 wordt cen 
voorbeeld gegeven van een, relatief on-
schadelijke, bijwerking op het tweede-
lijns antireumaticum sulfasalazine: de 
versnelde afbraak van rode bloedcellen 
(hémolyse). De consequentie van deze 
bijwerking is, dat er een verstoring van de 
relatie tussen het hemoglobine gehalte 
(de rode kleurstof in de rode bloedcel-
len) en de ziekte-activiteit optreedt, zo-
dat het hemoglobine gehalte minder ge-
schikt wordt als variabele ter evaluatie 
van het effect van de sulfasalazinethe-
rapie. 
Een ander voorbeeld van een bijwerking 
opgetreden tijdens therapie met een 
tweede-lijns antireumaticum, azathio-
prine, is het ontstaan van galbulten (urti-
caria). De patiënte met deze bijwerking, 
beschreven in hoofdstuk 4, maakte in het 
verleden eveneens bijwerkingen door op 
goudinjecties, sulfasalazine en goudta-
bletten. Mogelijk dat haar sterk verlaagd 
gehalte van het 'afweer-eiwit' IgA een 
versterkte 'vatbaarheid' voor het ont-
staan van bijwerkingen weerspiegelt. In 
hoofdstuk 4 wordt eveneens een patiënte 
beschreven, die een sterke daling van het 
aantal bloedplaatjes (thrombocytope-
nic) ontwikkelde, tijdens het gebruik van 
drie verschillende DMARD's: goudin-
jecties, sulfasalazine en hydroxychloro-
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quine. De telkens optredende thrombo-
cytopenie is bij deze patiente mogelijk 
een uiting van een erfelijk bepaalde 
(HLA-DR3 en HLA-B8) afwijkende re-
actie van het afweersysteem op tweede-
lijns antircumatica. 
In samenwerking met de afdeling Reu-
matische Ziekten van het Academisch 
Ziekenhuis Groningen werd het gebruik 
van antireumatica door patiënten met 
een recent ontstane RA bestudeerd. 
Naast de gebruikelijke controles bij de 
behandelend reumatoloog werden de 
patiënten maandelijks door een van de 
speciaal opgeleide onderzoeksverpleeg-
kundigen gezien. Deze verzamelde kli-
nische gegevens, zoals het aantal pijnlijke 
en gezwollen gewrichten, en zag erop 
toe, dat op vaste tijdstippen bloedcon-
troles en röntgenonderzoek werd ver-
richt. Op gestandaardiseerde wijze werd 
naar eventuele bijwerkingen gevraagd. 
Opgetreden bijwerkingen werden zo 
goed mogelijk in kaart gebracht. Van de 
gebruikte medicamenten werd de start-
en stopdatum, de dosering en de reden 
van verandering in medicatie nauwkeu-
rig vastgelegd. 
In hoofdstuk 5 wordt verslag gedaan van 
de huidbijwerkingen ontstaan tijdens 
therapie met goudinjecties bij patiënten, 
welke op bovengenoemde protocollaire 
wijze vervolgd werden. Veertien van de 
47 patiënten behandeld met goudinjec-
ties ontwikkelden een dermate ernstige 
huidreactie, dat de goudtherapie ge-
staakt werd dan wel de dosering ver-
laagd. Bij 3 van deze patiënten paste de 
huidafwijking bij een overgevoeligheids-
reactie voor nikkel. Waarschijnlijk werd 
gemaakt, dat het ontstaan van de op-
vlamming, dan wel de inductie, van de 
contactallergie voor nikkel veroorzaakt 
werd door de goudlherapie. 
De effectiviteit en veiligheid van niet ste-
roide anti-inflammatoire geneesmiddel-
en wordt veelal bestudeerd in relatief 
kortdurende onderzoeken onder speci-
fieke onderzoeksomstandigheden bij ge-
selecteerde patiëntengroepen. Informa-
tie betreffende effectiviteit en toxiciteit 
op de lange termijn en in de 'praktijk van 
alle dag' is dan ook schaars. In hoofdstuk 
6 wordt verslag gedaan van het NS AID 
gebruik op lange termijn door de in Nij-
megen protocollair vervolgde RA pa-
tiënten. Ondanks het grote aantal ver-
schillende NSAID's op de Nederlandse 
markt lijkt slechts een klein aantal 
NSAID's voldoende om het merendeel 
van de RA patiënten gedurende enkele 
jaren, naast het gebruik van tweede-lijns 
antireumatica, adequaat te behandelen. 
Tevens blijkt dat therapie onderbreking-
en, hetzij wegens gebrek aan effect, hetzij 
wegens bijwerkingen ook na langere tijd 
voorkomen, hetgeen de tekortkomingen 
van korte termijn studies nogmaals on-
derstreept. Met behulp van 'levensduur 
analyse' met in plaats van 'overlijden' 
stoppen van de NSAID's wegens bijwer-
kingen of gebrek aan effect als eindpunt 
werd een indruk verkregen van de tox-
iciteit en effectiviteit van naproxen, in-
domethaeïne en diclofenac. Wat betreft 
stoppen van therapie wegens gebrek aan 
effect wordt géén verschil tussen de drie 
genoemde NSAID's gevonden. Echter, 
wanneer naar het optreden van bijwer-
kingen als reden tot staken gekeken 
wordt, blijkt indomethacine er in ongun-
stige zin uit te springen. Het geslacht, de 
leeftijd en de ziekte-activiteit aan het be-
gin van de therapie blijken niet van in-
vloed, noch op het stoppen wegens on-
voldoende effect, noch op het stoppen 
wegens toxiciteit. 
De resultaten van de studie naar het lan-
ge termijn gebruik van DMARD's door 
de zowel in Nijmegen als in Groningen 
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protocollair vervolgde RA patiënten 
worden beschreven in hoofdstuk 7. Het 
blijkt dat meer dan de helft van de pa-
tiënten de tweede-lijns therapie binnen 
twee jaar moet staken wegens het uit-
blijven van effect dan wel wegens het 
optreden van bijwerkingen. Met behulp 
van 'levensduur analyse' kon op verge-
lijkbare wijze als bij de NSAID's een 
indruk verkregen worden van de effecti-
viteit en toxiciteit van hydroxychloroqui-
ne, sulfasalazine, aurothioglucose en d-
penicillamine. Na correctie voor "versto-
rende variabelen' als de ziekte-activiteit 
aan het begin van de behandeling en de 
volgorde waarin de DMARD's werden 
voorgeschreven, kon de 'overleving' van 
hydroxychloroquine, sulfasalazine, 
goudinjecties en d-penicillamine met el-
kaar vergeleken worden. Wanneer sta-
ken van de therapie wegens toxiciteit als 
eindpunt genomen wordt, blijkt de 'over-
leving' van de goudinjecties korter te zijn 
dan die van hydroxychloroquine. Wordt 
echter gekeken naar onvoldoende effect 
van de therapie, dan blijkt de Overleving' 
van aurothioglucose en sulfasalazine 
groter dan die van hydroxychloroquine. 
Ook wordt gevonden dat het staken van 
hydroxychloroquine, sulfasalazine en d-
penicillamine wegens bijwerkingen zich 
beperkt tot het eerste jaar van voorschrij-
ven, terwijl aurothtoglucose ook na dat 
eerste jaar nog gestopt moet worden. Het 
staken wegens gebrek aan effect komt bij 
alle vier de genoemde DMARD's ge-
durende ongeveer de eerste twee jaar 
voor. 
In hoofdstuk 8 wordt nagegaan welke 
factoren van invloed zijn op de 'over-
leving' van de DMARD's. Wanneer naar 
staken van therapie wegens bijwerkingen 
wordt gekeken, blijken een verhoogde 
leeftijd, een verhoogde serum con-
centratie van het 'afweer-eiwit' IgA en 
bepaalde erfelijke factoren (vrouwelijk 
geslacht, HLA-DR3) de behandelduur 
van aurothioglucose nadelig te beïnvloe-
den. De 'overleving' van sulfasalazine 
wordt verkort naarmate de leeftijd hoger 
en het aantal eerder voorgeschreven 
DMARD's groter is. Met betrekking tot 
gebrek aan effect blijkt een hoge ziekte-
activiteit aan het begin van de therapie 
tot staken van de behandeling met hy-
droxychloroquine, sulfasalazine en d-pe-
nicillamine te predisponeren. Ook blijkt 
het aantal voorafgaande DMARD's van 
invloed op de 'overleving' van sulfasala-
zine. Interessant is dat de erfelijke factor 
(HLA-DR3), die in de literatuur met een 
zeer goede effectiviteit van goudinjecties 
in verband gebracht wordt, in onze studie 
geassocieerd is met een lange 'overle-
ving' van hydroxychloroquine. Echter, de 
grootte van het effect van deze factoren 
is klein en de interindividuele verschillen 
zijn aanzienlijk, zodat de klinische toe-
pasbaarheid van deze factoren beperkt 
blijft. Wel kan kennis van deze factoren 
van belang zijn voor de interpretatie van 
onderzoeksgegevens uit de literatuur. 
Tijdens behandeling met tweede-lijns 
antireumatica worden geen verschillen 
in het beloop van mogelijke risico facto-
ren voor het ontstaan van bijwerkingen 
gevonden tussen patiënten, die de twee-
de-lijns antireumatica moeten stoppen 
wegens bijwerkingen en hen, die dat niet 
hoeven. 
Vaak wordt verondersteld, dat de ziekte 
RA zelf een risicofactor is voor het ont-
staan van bijwerkingen tijdens tweede-
lijns medicatie. Zo wordt aangenomen, 
dat het vóórkomen van bijwerkingen tij-
dens sulfasalazine therapie groter is bij 
patiënten met RA dan bij patiënten met 
ontstekingsachtige darmziekten (Inflam-
matory Bowel Disease, IBD; waaronder 
vallen de ziekte van Crohn en 'colitis ul-
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Samenvatting 
cerosa')· Om antwoord te kunnen geven 
op de vraag of de ziekte RA op zich 
inderdaad een risicofactor is, verrichtten 
wij een zogenaamde 'meta-analyse' van 
de literatuur. Hierin werden de resul-
taten van 49 afzonderlijke klinische stu-
dies, waarin sulfasalazine aan RA, IBD 
patiënten en aan patiënten met een zo-
genaamde seronegatievc spondylarthro-
pathie (SSpA, waaronder hier verstaan 
wordt: de ziekte van Bechterew, artritis 
bij de huidziekte psoriasis en na bepaal-
de infectieziekten = 'reactieve artritis') 
werd voorgeschreven, gebundeld 
(hoofdstuk 9). Het bijwerkingsproficl 
blijkt niet te verschillen voor de verschil-
lende indicaties. Het risico voor stoppen 
van sulfasalazine therapie wegens bij-
werkingen lijkt op het eerste gezicht in-
derdaad groter voor RA patiënten ver-
geleken met IBD of SSpA patiënten. 
Echter, bij het berekenen van deze risi-
co's is geen rekening gehouden met ver-
schillen in de drie patiëntengroepen wat 
betreft studie-opzet, leeftijds- en ge-
slachlsverdeling, dosis, het gebruik van 
tabletten met of zonder maagbescher-
mende laag ('enteric coated'), percent-
age patiënten voor het eerst behandeld 
met sulfasalazine, en de aard van de be-
handeling (onderhouds- versus behan-
deling van actieve ziekte). Van deze fac-
toren blijken met name - in volgorde van 
belangrijkheid - de leeftijd, het percent-
age patiënten voor het eerst behandeld 
met sulfasalazine en de dosis van sta-
tistisch significant belang. Na correctie 
voor deze drie verstorende variabelen 
blijken de eerder gevonden verschillen in 
risico voor beëindiging van therapie voor 
RA ten opzichte van IBD en SSpA pa-
tiënten te verdwijnen. Dus, de ziekte reu-
matoïde artritis op zich is geen risico-
factor voor het ontstaan van bijwerking-
en. Het vaak veronderstelde verhoogde 
risico blijkt te berusten op selectie van de 
patiëntengroepen ten aanzien van de 
leeftijd, het percentage patiënten voor 
het eerst met sulfasalazine behandeld en 
de dosering. 
In hoofdstuk 10 worden de belangrijkste 
conclusies van dit proefschrift samenge-
vat. 
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CURRICULUM VITAE 
De auteur van dit proefschrift werd op 19 januari 1961 te Maastricht geboren. In 1979 
behaalde hij het einddiploma Gymnasium β aan het voormalig Henric van Veldekc 
College te Maastricht. Vervolgens studeerde hij Geneeskunde aan de Katholieke 
Universiteit te Nijmegen. Het doctoraalexamen werd in februari 1984 afgelegd en het 
artsexamen in 1986. Vanaf juni 1986 was hij als Assistent-Geneeskundige-Niet-In-
Opleiding (AGNIO) werkzaam achtereenvolgens in de Kliniek voor Inwendige Ziek­
ten (hoofd: Prof. Dr. A. van 't Laar) van het Academisch Ziekenhuis te Nijmegen en 
binnen de afdelingen Reumatische Ziekten van het De Wever Ziekenhuis te Heerlen 
en van het Maasland Ziekenhuis te Sittard (Dr. H. Goei The; Dr. H. Houben). 
Van januari 1988 tot december 1990 was hij werkzaam op de afdeling Reumatische 
Ziekten van het Academisch Ziekenhuis te Nijmegen (hoofd: Prof. Dr. L. van de 
Putte), in welke periode het in dit proefschrift beschreven onderzoek werd verricht. 
Sedert december 1990 is hij werkzaam als Assistent-Geneeskundige-In-Opleiding 
(AGIO) binnen de afdeling Inwendige Ziekten van het Mariaziekenhuis te Tilburg 
(opleider: Dr. L.G. van Doorn). In februari 1991 ontving hij de Prof. Dr. J. Goslings-
prijs van de Nederlandse Vereniging voor Rheumatologen. 
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STELLINGEN 
behorende bij het proefschrift 
SIDE EFFECTS OF ANTIRHEUMATIC DRUGS 
a survey of risk factors 
Math J.H. Wijnands 
1. Individuele risicofactoren voor het ontstaan van bijwerkingen op twcede-lijns 
antireumatica hebben weinig of geen betekenis voor de klinische praktijk (dit 
proefschrift). 
2. Bij de beoordeling van de ziekte-activiteit van reumatoïde artritis patiënten 
tijdens behandeling met sulfasalazine dient het hemoglobine gehalte niet als 
proces variabele gebruikt te worden (dit proefschrift). 
3. Zowel edelsmid als reumatoloog dienen bij het verstrekken van 'goud-pre-
paraten' met het induceren van een contactallergie voor nikkel rekening te 
houden (dit proefschrift). 
4. Overlevings-analyse is een bruikbare methode om geïnformeerd te geraken over 
de toxiciteit en effectiviteit van geneesmiddelen op de lange termijn en in de 
praktijk van alle dag. 
5. Bij de behandeling van reumatoïde artritis patiënten blijkt in de dagelijkse 
praktijk het NSAID indomelhacine sneller gestopt te worden wegens bijwer-
kingen dan naproxen en diclofenac (dit proefschrift). 
6. Bij de behandeling van reumatoïde artritis patiënten met tweede-lijns anti-
reumatica blijkt hydroxychloroquine sneller gestaakt te worden wegens gebrek 
aan effect dan aurothioglucose en sulfasalazine (dit proefschrift). 
7. Wanneer stoppen van de therapie wegens gebrek aan effect als eindpunt wordt 
genomen, blijkt een grote initiële ziekte-activiteit de behandelduur van sul-
fasalazine, hydroxychloroquine en d-penicillamine te bekorten. 
8. Reumatoïde artritis patiënten hebben niet méér kans sulfasalazine therapie te 
moeten onderbreken vanwege een bijwerking dan patiënten met een inflam-
matoire darmziekle. Het vaak veronderstelde verhoogde risico voor reumatoïde 
artritis patiënten berust op selectie met name ten aanzien van de leeftijd en het 
al dan niet eerder voorgeschreven zijn van sulfasalazine (dit proefschrift). 
9. In tegenstelling tot de concentratie in het serum daalt het speeksel IgA gehalte 
tijdens tweede-lijns medicatie met hydroxychloroquine, sulfasalazine of au-
rothioglucose niet (eigen waarneming). 
10. Lymfoedcem bij reumatoïde artritis wordt waarschijnlijk veroorzaakt door chro-
nische obliteratieve lymfangitis. (Wijnands MJH, Corstens FHM, Van der 
Heijde DMFM, Van de Putte LBA, Lenders JWM. Neth J Med 1988;33:140-
143). 
11. Bij een (peri)artritis gepaard gaande met pijnlijke nodulaire huidinfiltraten 
dient aan een maligniteit van het pancreas gedacht te worden en het scrum lipase 
bepaald te worden (Wijnands MJH, Houben HHNL, Bos LP, Oswald FH, Van 
der Tempel H. Ned Tijdschr Geneeskd 1988;132:1511-2). 
12. Het eten van zoute drop wordt door xerostomie patiënten als uiterst onaan-
genaam ervaren (eigen waarneming). 
13. Patiënten, die ver van academische ziekenhuizen wonen, komen ten onrechte 
vaker daar terecht op advies van buren, familie en kennissen dan via verwijzing 
van artsen. 
14. Bij het zelf bereiden van een gerecht is de kwaliteit van de maaltijd helaas vaak 
gerelateerd aan de kwantiteit van de vaat (eigen waarneming). 
15. Een wetenschappelijke publicatie wordt vaak ten onrechte naar het aantal 
referenties op waarde geschat (eigen waarneming). 
Math Wijnands 
Nijmegen, 20 juni 1991 



